Document:

EXHIBIT 10.10

 

SECURITIES
PURCHASE AGREEMENT

 

Dated as of January 17, 2017

 

Xtant Medical Holdings, Inc.

600 Cruiser Lane

Belgrade, Montana 59714

 

Ladies and Gentlemen:

 

Each of the undersigned hereby confirms
its agreement with you as follows:

 

		1.	This Securities Purchase Agreement (this “Agreement”) is made as of the
date hereof between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and the Investors
listed on the signature pages hereto (the “Investors”). The Investors hold Convertible Promissory Notes issued
by the Company pursuant to the Securities Purchase Agreement, dated as of April 14, 2016 (the “Notes”), in the
aggregate principal amount of $2,238,166.

 

		2.	The Company is proposing to issue and sell to the Investors $67,145 aggregate principal
amount of convertible senior notes due 2021 (the “Securities”), which are convertible into shares of
the Company’s common stock, par value $0.000001 per share (the “Common Stock”). The Securities
will be entitled to the benefits of a Registration Rights Agreement (the “Registration Rights Agreement”), to
be entered into among the Company and the Investors, pursuant to which the Company will agree, among other things, to file and
cause to become effective under the Securities Act of 1933, as amended (the “Securities Act”), a registration
statement covering the resale of the Securities and the Common Stock issuable upon conversion of the Securities.

 

		3.	The purchase price for the Securities shall be paid by a dollar-for-dollar offset against all interest due to the Investors
as of the closing under the Notes.

 

		4.	The Securities shall have the terms set forth in each of the convertible promissory notes (the
“Notes”) in the form attached hereto as Exhibit A, to be issued on the date hereof to each of the Investors.

 

		5.	The Company and each Investor agrees that, upon the terms and subject to the conditions set forth
herein, each Investor will purchase from the Company and the Company will issue and sell to each Investor the aggregate principal
amount of the Securities set forth below on such Investor’s signature page for the aggregate purchase price set forth below
on such Investor’s signature page. The Securities shall be purchased pursuant to the Terms and Conditions for Purchase of
Securities attached hereto as Annex A and incorporated herein by reference as if fully set forth herein.

 

     

     

    

 

Aggregate Principal Amount of Securities the Investor Agrees
to Purchase:

 

$42,856.59

 

Aggregate Purchase Price of such Securities:
$42,856.59

 

Please confirm that the foregoing correctly sets forth the agreement
between us by signing in the space provided below for that purpose.

 

AGREED AND ACCEPTED BY:

 

 

 

	
        Xtant Medical Holdings, Inc.

        a Delaware corporation
	 	
        Name of Investor:

        ROS Acquisition Offshore LP

	 	 	 
	 	 	
        By OrbiMed Advisors LLC, solely in its

        capacity as Investment Manager

	 	 	 	 	 
	By:	/s/ Daniel Goldberger	 	By:	/s/ W. Carter Neild
	Name:    Daniel Goldberger	 	Print Name:     W. Carter Neild
	Title:      Chief Executive Officer	 	Title:                 Member

 

     

     

    

 

Aggregate Principal Amount of Securities the Investor Agrees
to Purchase:

 

$24,288.41

 

Aggregate Purchase Price of such Securities:
$24,288.41

 

Please confirm that the foregoing correctly sets forth the agreement
between us by signing in the space provided below for that purpose.

 

AGREED AND ACCEPTED BY:

 

 

 

	
        Xtant Medical Holdings, Inc.

        a Delaware corporation
	 	
        Name of Investor:

        OrbiMed Royalty Opportunities II, LP

	 	 	 
	 	 	
        By OrbiMed ROF II LLC,

        Its General Partner

	 	 	 
	 	 	
        By OrbiMed Advisors LLC,

        its Managing Member

	 	 	 	 	 
	By: 	/s/ Daniel Goldberger	 	By: 	/s/ W. Carter Neild
	Name:     Daniel Goldberger	 	Print Name:    W. Carter Neild
	Title:       Chief Executive Officer	 	Title:                Member

 

     

     

    

 

ANNEX A
TO THE SECURITIES PURCHASE AGREEMENT

TERMS AND
CONDITIONS FOR PURCHASE OF SECURITIES

 

		1.	Authorization and Sale of Securities. The Company is proposing to sell $67,145 aggregate
principal amount of the Securities to the Investors.

 

		2.	Agreement to Sell and Purchase the Securities. Upon the terms and subject to the conditions
hereinafter set forth, at the Closing (as defined in Section 3.1), the Company will sell to each Investor, and each Investor
will purchase from the Company, the aggregate principal amount of Securities set forth on such Investor’s signature page
hereto at the purchase price set forth on such signature page.

 

		3.	Closings and Delivery of Securities and Funds.

 

		3.1	The completion of the purchase and sale of the Securities (the “Closing”) shall
occur on January 17, 2017 (the “Closing Date”).

 

		3.2	The Company’s obligation to issue and sell the Securities to the Investors shall be subject
to the following conditions, any one or more of which may be waived by the Company: (a) the accuracy of the representations and
warranties made by the Investors and (b) the fulfillment of those undertakings of the Investors to be fulfilled prior to the Closing.

 

		3.3	Each Investor’s obligation to accept delivery of the Securities and to pay for the Securities
shall be subject to the following conditions, any one or more of which may be waived by such Investor: (a) each of the representations
and warranties of the Company made in Section 4 shall be accurate in all material respects as of the Closing Date; (b) delivery
of an officer’s certificate dated as of the Closing Date regarding the accuracy in material respects of the Company’s
representations and warranties and addressing such other matters as are customarily addressed in closing certificates; (c) delivery
to the Investors of a customary secretary’s certificate in form reasonably acceptable to the Investors; (d) the Company and
the Investors shall have executed the Registration Rights Agreement; (e) the Company shall have issued a Note, in the form attached
hereto as Exhibit A, to each of the Investors and (f) the Company shall have furnished to the Investors such further
documents as the Investors may reasonably request.

 

		3.4	At the Closing, the purchase price for the Securities shall be paid by each Investor by a dollar-for-dollar
offset against all interest due to the Investor as of the Closing under the Notes. Such offset shall have the same affect as if
the Investor paid cash to the Company for such Securities and the Company used such cash to pay to the Investor the interest so
offset.

 

    	 	A-1	 

     

    

 

		4.	Representations, Warranties and Covenants of the Company.

 

The Company hereby
represents and warrants to, and covenants with, each Investor that:

 

		4.1	When the Notes are issued and delivered pursuant to this Agreement, such Notes will not be of the
same class (within the meaning of Rule 144A under the Securities Act) as securities of the Company that are listed on a national
securities exchange registered under Section 6 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or that are quoted in a U.S. automated inter-dealer quotation system.

 

		4.2	Assuming the accuracy of each Investor’s representations and warranties in Section 5,
the purchase and resale of the Notes pursuant hereto are exempt from the registration requirements of the Securities Act.

 

		4.3	No form of general solicitation or general advertising within the meaning of Regulation D under
the Securities Act (including, but not limited to, advertisements, articles, notices or other communications published in any newspaper,
magazine or similar medium or broadcast over television or radio, or any seminar or meeting whose attendees have been invited by
any general solicitation or general advertising) was used by the Company, any of its affiliates or any of its representatives (other
than you, as to whom the Company makes no representation) in connection with the offer and sale of the Notes.

 

		4.4	None of the Company or any other person acting on its behalf has sold or issued any securities
that would be integrated with the offering of the Notes contemplated by this Agreement pursuant to the Securities Act, the rules
and regulations thereunder or the interpretations thereof by the Securities and Exchange Commission (the “Commission”)
in a manner that would require the registration, under the Securities Act, of the sale of the Notes contemplated by this Agreement.

 

		4.5	Each of the Company and its subsidiaries has been duly organized, is validly existing and in good
standing as a corporation, partnership or limited liability company, as applicable, under the laws of its jurisdiction of organization
and is duly qualified to do business and in good standing as a foreign corporation or other business entity in each jurisdiction
in which its ownership or lease of property or the conduct of its businesses requires such qualification, except where the failure
to be so qualified or in good standing could not, individually or in the aggregate, reasonably be expected to (i) have a material
adverse effect on the condition (financial or otherwise), results of operations, stockholders’ equity, properties, business
or prospects of the Company and its subsidiaries taken as a whole or (ii) materially interfere with the consummation of the transactions
contemplated hereby (collectively, a “Material Adverse Effect”). Each of the Company and its subsidiaries has
all power and authority necessary to own or hold its properties and to conduct the businesses in which it is engaged. As of the
date of this Agreement, the Company has no subsidiaries other than Bacterin International, Inc., X-spine Systems Inc. and Xtant
Medical, Inc. and no “significant subsidiaries” (as defined in Rule 405 under the Securities Act) other than Bacterin
International, Inc. and X-spine Systems Inc.

 

    	 	A-2	 

     

    

 

		4.6	The Company has an authorized capitalization as set forth in the publicly available Annual Report
on Form 10-K filed with the Commission for the fiscal year ended December 31, 2015, and all of the issued shares of capital stock
of the Company have been duly authorized and validly issued and are fully paid and non-assessable. All of the issued shares of
capital stock or other ownership interest of each subsidiary of the Company have been duly authorized and validly issued, are fully
paid and non-assessable and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities
or claims, except for such liens, encumbrances, equities or claims as could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.

 

		4.7	The Company has all requisite corporate power and authority to execute, issue, sell and perform
its obligations under the Notes. The Notes have been duly authorized by the Company and, when duly executed by the Company, will
be validly issued and delivered and will constitute valid and binding obligations of the Company entitled to the benefits of the
Registration Rights Agreement, enforceable against the Company in accordance with their terms, except as such enforceability may
be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium, and other laws relating to or affecting
creditors’ rights generally and by general equitable principles (regardless of whether such enforceability is considered
in a proceeding in equity or at law).

 

		4.8	The Company has all requisite corporate power and authority to execute, deliver and perform its
obligations under the Registration Rights Agreement. The Registration Rights Agreement has been duly and validly authorized by
the Company, and upon its execution and delivery and, assuming due authorization, execution and delivery by the other parties thereto,
will constitute the valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except
as such enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium, and other laws
relating to or affecting creditors’ rights generally and by general equitable principles (regardless of whether such enforceability
is considered in a proceeding in equity or at law).

 

		4.9	The Company has all the requisite corporate power and authority to issue the Common Stock issuable
upon conversion of the Notes (the “Underlying Common Stock”). The Underlying Common Stock has been duly and
validly authorized by the Company and, and when issued upon conversion of the Notes, in accordance with the terms of the Notes,
will be validly issued, fully paid and non-assessable, and the issuance of the Underlying Common Stock will not be subject to any
preemptive or similar rights.

 

		4.10	The Company has all requisite corporate power to execute, deliver and perform its obligations under
this Agreement. This Agreement has been duly and validly authorized, executed and delivered by the Company.

 

    	 	A-3	 

     

    

 

		4.11	The issue and sale of the Notes, the issuance of the Underlying Common Stock upon conversion of
the Notes, the execution, delivery and performance by the Company of the Notes, the Registration Rights Agreement and this Agreement
and the consummation of the transactions contemplated hereby and thereby, will not (i) conflict with or result in a breach or violation
of any of the terms or provisions of, impose any lien, charge or encumbrance upon any property or assets of the Company or its
subsidiaries, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement, license, lease or other agreement
or instrument to which the Company or any of its subsidiaries is a party or by which any of them is bound or to which any of their
respective properties or assets is subject, (ii) result in any violation of the provisions of the charter or by-laws (or similar
organizational documents) of the Company or any of its subsidiaries, or (iii) result in any violation of any statute or any judgment,
order, decree, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its
subsidiaries or any of their respective properties or assets, except, with respect to clauses (i) and (iii), conflicts or violations
that could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect and except as set forth
in the Public Disclosure Documents.

 

		4.12	No consent, approval, authorization or order of, or filing, registration or qualification with
any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their respective
properties or assets is required for the issue and sale of the Notes, the issuance of the Underlying Common Stock upon conversion
of the Notes, the execution, delivery and performance by the Company of the Notes, the Registration Rights Agreement and this Agreement,
and the consummation of the transactions contemplated hereby, except for such consents, approvals, authorizations, orders, filings,
registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase of the
Notes.

 

		4.13	The Company maintains a system of internal control over financial reporting (as such term is defined
in Rule 13a-15(f) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed by, or
under the supervision of, the Company’s principal executive and principal financial officers, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles in the United States. The Company maintains internal accounting controls sufficient
to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorization,
(ii) transactions are recorded as necessary to permit preparation of the Company’s financial statements in conformity with
accounting principles generally accepted in the United States and to maintain accountability for its assets, (iii) access to the
Company’s assets is permitted only in accordance with management’s general or specific authorization, and (iv) the
recorded accountability for the Company’s assets is compared with existing assets at reasonable intervals and appropriate
action is taken with respect to any differences. As of the date of the most recent balance sheet of the Company and its consolidated
subsidiaries reviewed or audited by EKS&H LLP and the audit committee of the board of directors of the Company, there were
no material weaknesses in the Company’s internal controls.

 

    	 	A-4	 

     

    

 

		4.14	The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e)
under the Exchange Act), (ii) such disclosure controls and procedures are designed to ensure that the information required to be
disclosed by the Company and its subsidiaries in the reports they file or submit under the Exchange Act is accumulated and communicated
to management of the Company and its subsidiaries, including their respective principal executive officers and principal financial
officers, as appropriate, to allow timely decisions regarding required disclosure to be made; and (iii) such disclosure controls
and procedures are effective in all material respects to perform the functions for which they were established.

 

		4.15	Since the date of the most recent balance sheet of the Company and its consolidated subsidiaries
reviewed or audited by EKS&H LLP and the audit committee of the board of directors of the Company, (i) the Company has not
been advised of or become aware of (A) any significant deficiencies in the design or operation of internal controls, that could
adversely affect the ability of the Company or any of its subsidiaries to record, process, summarize and report financial data,
or any material weaknesses in internal controls, and (B) any fraud, whether or not material, that involves management or other
employees who have a significant role in the internal controls of the Company and each of its subsidiaries; and (ii) there have
been no significant changes in internal controls or in other factors that could significantly affect internal controls, including
any corrective actions with regard to significant deficiencies and material weaknesses.

 

		4.16	There is and has been no failure on the part of the Company and any of its directors or officers,
in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated
in connection therewith.

 

		4.17	Since the date of the latest audited financial statements included in the Public Disclosure Documents
(as defined below) and except as disclosed therein, neither the Company nor any of its subsidiaries has (i) sustained any loss
or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any
labor disturbance or dispute or court or governmental action, order or decree, (ii) issued or granted any securities (other than
pursuant to (x) employee benefit plans, qualified stock option plans, other employee compensation plans or non-employee director
compensation programs in existence on the date hereof and described in the Public Disclosure Documents or (y) options, warrants
or rights outstanding on the date hereof, (iii) incurred any liability or obligation, direct or contingent, other than liabilities
and obligations that were incurred in the ordinary course of business, (iv) entered into any transaction not in the ordinary course
of business (other than as described in the Public Disclosure Documents (without giving effect to any supplements or amendments
thereto after the execution and delivery of this Agreement)), or (v) declared or paid any dividend on its capital stock, and, since
such date, there has not been any change in the capital stock, partnership or limited liability company interests, as applicable,
or long-term debt of the Company or any of its subsidiaries (other than as described in the Public Disclosure Documents (without
giving effect to any supplements or amendments thereto after the execution and delivery of this Agreement)) or any adverse change,
or any development involving a prospective adverse change, in or affecting the condition (financial or otherwise), results of operations,
stockholders’ equity, properties, management, business or prospects of the Company and its subsidiaries, taken as a whole,
in each case except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The
reports required to be filed by the Company under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, together
with any materials filed or furnished by the Company under the Exchange Act, whether or not any such reports were required, are
referred to herein, collectively, as the “Public Disclosure Documents”.

 

    	 	A-5	 

     

    

 

		4.18	The Company and each of its subsidiaries has good and marketable title in fee simple to all real
property and good and marketable title to all personal property owned by them, in each case free and clear of all liens, encumbrances
and defects, except to the extent such liens, encumbrances and defects do not materially affect the value of such property and
do not materially interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries.
All assets held under lease by the Company or any of its subsidiaries are held by them under valid, subsisting and enforceable
leases, with such exceptions as do not materially interfere with the use made and proposed to be made of such assets by the Company
or any of its subsidiaries.

 

		4.19	The Company and each of its subsidiaries have, and have operated in compliance with, such permits,
licenses, patents, franchises, certificates of need, exemptions, clearances and other approvals or authorizations of governmental
or regulatory authorities (“Permits”) as are necessary under applicable law to own their properties and conduct
their businesses in the manner described in the Public Disclosure Documents, except for any of the foregoing that could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and each of its subsidiaries have fulfilled
and performed all of its obligations with respect to the Permits, and no event has occurred that allows, or after notice or lapse
of time would allow, revocation or termination thereof or results in any other impairment of the rights of the holder or any such
Permits, except for any of the foregoing that could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. Neither the Company, nor any of its subsidiaries has received written notice of any revocation, termination or
modification of any such Permits or otherwise has any reason to believe that any such Permits will be revoked, terminated or modified
or not be renewed in the ordinary course.

 

    	 	A-6	 

     

    

 

		4.20	The Company and its subsidiaries own, or have obtained valid and enforceable licenses for, or other
rights to use, the inventions, patent applications, patents, trademarks (both registered and unregistered), tradenames, service
names, copyrights, trade secrets and other proprietary information described in Public Disclosure Documents as being owned or licensed
by them or which are necessary for the conduct of their respective businesses as currently conducted or as proposed to be conducted
(including the commercialization of products or services described in the Public Disclosure Documents as under development), except
where the failure to own, license or have such rights could not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect (collectively, “Intellectual Property”). Except as disclosed in Public Disclosure
Documents, and except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect,
(i) there are no third parties who have or, to the Company’s knowledge, will be able to establish rights to any Intellectual
Property, except for, and to the extent of, the ownership rights of the owners of the Intellectual Property which the Public Disclosure
Documents disclose is licensed to the Company or any of its subsidiaries; (ii) to the Company’s knowledge, there is no infringement
by third parties of any Intellectual Property; (iii) there is no pending or, to the Company’s knowledge, threatened action,
suit, proceeding or claim by others challenging the Company’s or its subsidiaries’ rights in or to any Intellectual
Property, and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or
claim; (iv) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging
the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which could form a
reasonable basis for any such action, suit, proceeding or claim; (v) there is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by others that the Company or any of its subsidiaries infringes or otherwise violates
(or would, upon the commercialization of any product or service described in the Public Disclosure Documents as under development,
infringe or violate) any patent, trademark, tradename, service name, copyright, trade secret or other proprietary rights of others,
and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (vi)
the Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been
licensed to the Company or any of its subsidiaries, and all such agreements are in full force and effect; (vii) to the Company’s
knowledge, there is no patent or patent application that contains claims that interfere with the issued or pending claims of any
of the Intellectual Property or that challenges the validity, enforceability or scope of any of the Intellectual Property; and
(viii) to the Company’s knowledge, there is no prior art that may render any patent application within the Intellectual Property
unpatentable that has not been disclosed to the U.S. Patent and Trademark Office.

 

		4.21	There are no legal or governmental proceedings pending to which the Company or any of its subsidiaries
is a party or of which any property or assets of the Company or any of its subsidiaries is the subject that could, individually
or in the aggregate, reasonably be expected to (i) have a Material Adverse Effect, except as described in the Public Disclosure
Documents, or (ii) have a material adverse effect on the performance by the Company of this Agreement, the Notes or the Registration
Rights Agreement or on the consummation of any of the transactions contemplated hereby or thereby. To the Company’s knowledge,
no such proceedings are threatened or contemplated by governmental authorities or others.

 

    	 	A-7	 

     

    

 

		4.22	Neither the Company nor any of its subsidiaries: (i) is in violation of its charter or by-laws
(or similar organizational documents), (ii) is in default, and no event has occurred that, with notice or lapse of time or both,
would constitute such a default, in the due performance or observance of any term, covenant, condition or other obligation contained
in any indenture, mortgage, deed of trust, loan agreement, license or other agreement or instrument to which it is a party or by
which it is bound or to which any of its properties or assets is subject, or (iii) is in violation of any statute or any order,
rule or regulation of any court or governmental agency or body having jurisdiction over it or its property or assets or has failed
to obtain any license, permit, certificate, franchise or other governmental authorization or permit necessary to the ownership
of its property or to the conduct of its business, except in the case of clauses (ii) and (iii), to the extent any such default,
violation or failure could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

		4.23	The Company and its subsidiaries and their respective properties, assets and operations are in
compliance with, and the Company and each of its subsidiaries hold all permits, authorizations and approvals required under, Environmental
Laws (as defined below), except to the extent that failure to so comply or to hold such permits, authorizations or approvals could
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Company’s knowledge,
there are no past, present or reasonably anticipated future events, conditions, circumstances, activities, practices, actions,
omissions or plans that, individually or in the aggregate, could reasonably be expected to give rise to any material costs or liabilities
to the Company or any of its subsidiaries under, or to interfere with or prevent compliance by the Company or any of its subsidiaries
with, Environmental Laws; except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect, neither the Company nor any of its subsidiaries (i) is the subject of any investigation, (ii) has received any notice or
claim, (iii) is a party to or affected by any pending or, to the Company’s knowledge, threatened action, suit or proceeding,
(iv) is bound by any judgment, decree or order or (v) has entered into any agreement, in each case relating to any alleged violation
of any Environmental Law or any actual or alleged release or threatened release or cleanup at any location of any Hazardous Materials
(as defined below) (as used herein, “Environmental Law” means any federal, state, local or foreign law, statute,
ordinance, rule, regulation, order, decree, judgment, injunction, permit, license, authorization or other binding requirement,
or common law, relating to health, safety or the protection, cleanup or restoration of the environment or natural resources, including
those relating to the distribution, processing, generation, treatment, storage, disposal, transportation, other handling or release
or threatened release of Hazardous Materials, and “Hazardous Materials” means any material (including, without
limitation, pollutants, contaminants, hazardous or toxic substances or wastes) that is regulated by or may give rise to liability
under any Environmental Law).

 

    	 	A-8	 

     

    

 

		4.24	The Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns
required to be filed through the date hereof, subject to permitted extensions, and have paid all taxes due, and no tax deficiency
has been determined adversely to the Company or any of its subsidiaries, nor does the Company have any knowledge of any tax deficiencies
that have been, or could reasonably be expected to be asserted against the Company and each of its subsidiaries, that could, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

		4.25	Neither the Company nor any of its subsidiaries is, and, after giving effect to the offer and sale
of the Notes and the application of the proceeds therefrom, none of them will be, an “investment company” within the
meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder.

 

		4.26	The Company and its affiliates have not taken, directly or indirectly, any action designed to or
that has constituted or that could reasonably be expected to cause or result in the stabilization or manipulation of the price
of any security of the Company in connection with the offering of the Notes.

 

		4.27	Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, after due
inquiry, any director, officer, agent, employee or other person associated with or acting on behalf of the Company or any of its
subsidiaries, has in the course of its actions for, or on behalf of, the Company or any of its subsidiaries: (i) used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made any
direct or indirect unlawful payment to any foreign or domestic government official, “foreign office” (as defined in
the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively, the “FCPA”))
or employee from corporate funds; (iii) violated or is in violation of any provision of the FCPA, the Bribery Act 2010 of the United
Kingdom, as amended, or any other applicable anti-corruption or anti-bribery laws or statutes; or (iv) made any bribe, rebate,
payoff, influence payment, kickback or other unlawful payment to any domestic government official, foreign official or employee;
and the Company and its subsidiaries and, to the knowledge of the Company, the Company’s affiliates have conducted their
respective businesses in compliance with the FCPA, the Bribery Act 2010 of the United Kingdom, as amended, and any other applicable
anti-corruption or anti-bribery laws or statutes, and have instituted and maintain policies and procedures designed to ensure,
and which are reasonably expected to continue to ensure, continued compliance therewith.

 

		4.28	The operations of the Company and its subsidiaries are and have been conducted at all times in
compliance in all material respects with applicable financial recordkeeping and reporting requirements of the Currency and Foreign
Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder
and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,
the “Money Laundering Laws”); and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws
is pending or, to the knowledge of the Company, threatened.

 

    	 	A-9	 

     

    

 

		4.29	Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, after due
inquiry, any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries (i) is currently subject
to or the target of any sanctions administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department,
the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant
sanctions authority (collectively, “Sanctions”); or (ii) located, organized or resident in a country that is
the subject of Sanctions (including, without limitation, Cuba, Iran, North Korea, Sudan, and Syria); and the Company will not directly
or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary,
joint venture partner or other person or entity, for the purpose of financing the activities of any person, or in any country or
territory, that currently is the subject or target of Sanctions or in any other manner that will result in a violation by any person
(including any person participating in the transaction whether as an underwriter, advisor, investor or otherwise) of Sanctions.
The Company and its subsidiaries have not knowingly engaged in for the past five (5) years, are not now knowingly engaged in, and
will not engage in, any dealings or transactions with any individual or entity, or in any country or territory, that at the time
of the dealing or transaction is or was the subject or target of Sanctions.

 

		4.30	There are no contracts or other documents that would be required to be described in a registration
statement filed under the Securities Act or filed as exhibits to a registration statement of the Company pursuant to Item 601(b)(10)
of Regulation S-K that have not been described in the Public Disclosure Documents.

 

		4.31	No relationship, direct or indirect, that would be required to be described in a registration statement
of the Company pursuant to Item 404 of Regulation S-K, exists between or among the Company and its subsidiaries, on the one hand,
and the directors, officers, stockholders, customers or suppliers of the Company and its subsidiaries, on the other hand, that
has not been described in the Public Disclosure Documents.

 

		4.32	No labor disturbance by or dispute with the employees of the Company or any of its subsidiaries
exists or, to the knowledge of the Company, is imminent that could, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect.

 

		4.33	None of the transactions contemplated by this Agreement (including, without limitation, the use
of the proceeds from the sale of the Notes), will violate or result in a violation of Section 7 of the Exchange Act, or any regulation
promulgated thereunder, including, without limitation, Regulations T, U and X of the Board of Governors of the Federal Reserve
System.

 

    	 	A-10	 

     

    

 

		4.34	The Company and each of its subsidiaries carry, or are covered by, insurance from insurers of recognized
financial responsibility in such amounts and covering such risks as is adequate for the conduct of their respective businesses
and the value of their respective properties and as is customary for companies engaged in similar businesses in similar industries.
All policies of insurance of the Company and its subsidiaries are in full force and effect; the Company and each of its subsidiaries
are in compliance with the terms of such policies in all material respects; and neither the Company nor any of its subsidiaries
has received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary
to be made in order to continue such insurance. Except as could not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect, there are no claims by the Company or any of its subsidiaries under any such policy or instrument
as to which any insurance company is denying liability or defending under a reservation of rights clause; and neither the Company
nor any such subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost
that could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

		4.35	Each “employee benefit plan” (within the meaning of Section 3(3) of the Employee Retirement
Security Act of 1974, as amended (“ERISA”)) for which the Company or any member of its “Controlled Group”
(defined as any organization which is a member of a controlled group of corporations within the meaning of Section 414 of the Internal
Revenue Code of 1986, as amended (the “Code”)) would have any liability (each a “Plan”) has
been maintained in compliance with its terms and with the requirements of all applicable statutes, rules and regulations including
ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has
occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption; (iii) with
respect to each Plan subject to Title IV of ERISA: (A) no “reportable event” (within the meaning of Section 4043(c)
of ERISA) has occurred or is reasonably expected to occur, (B) no Plan is or is reasonably expected to be “at risk”
status (within the meaning of Section 430 of the Code or Section 303 of ERISA), (C) there has been no filing pursuant to Section
412(c) of the Code or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any
Plan or the receipt by the Company or any member of its Controlled Group from the Pension Benefit Guaranty Corporation or the plan
administrator of any notice relating to the intention to terminate any Plan or Plans or to appoint a trustee to administer any
Plan, (D) no conditions contained in Section 303(k)(1)(A) of ERISA for imposition of a lien shall have been met with respect to
any Plan and (E) neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability
under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation in the ordinary
course and without default) in respect of a Plan (including a “multiemployer plan”, within the meaning of Section 4001(c)(3)
of ERISA) (“Multiemployer Plan”); (iv) no Multiemployer Plan is, or is expected to be, “insolvent”
(within the meaning of Section 4245 of ERISA), in “reorganization” (within the meaning of Section 4241 of ERISA), or
in “endangered” or “critical” status (within the meaning of Section 432 of the Code or Section 304 of ERISA);
and (v) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether
by action or by failure to act, which would cause the loss of such qualification.

 

    	 	A-11	 

     

    

 

		4.36	No subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends
to the Company, from making any other distribution on such subsidiary’s capital stock or other ownership interests, from
repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s
property or assets to the Company or any other subsidiary of the Company, except as described in the Public Disclosure Documents.

 

		4.37	Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding
with any person (other than this Agreement) that could give rise to a valid claim against any of them for a brokerage commission,
finder’s fee or like payment in connection with the sale of the Notes.

 

		4.38	Neither the Company nor any of its subsidiaries is in violation of or has received notice of any
violation with respect to any federal or state law relating to discrimination in the hiring, promotion or pay of employees, nor
any applicable federal or state wage and hour laws, nor any state law precluding the denial of credit due to the neighborhood in
which a property is situated, the violation of any of which could, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect.

 

    	 	A-12	 

     

    

 

		4.39	Except as described in the Public Disclosure Documents, and except, in each case, where such event
could not, individually or in the aggregate, reasonably be expect to have a Material Adverse Effect, the Company and each of its
subsidiaries: (i) has not received any unresolved U.S. Food and Drug Administration (“FDA”) or similar
governmental agency or body (“Governmental Authority”) written notice of inspectional observations, Form 483,
written notice of adverse filing, warning letter, untitled letter or other similar correspondence or notice from the FDA, or any
other court or arbitrator or federal, state, local or foreign governmental or regulatory authority, alleging or asserting material
noncompliance with the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.), or received any written requests or
requirements to make material changes to the Company products by the FDA or any other Governmental Authority, (ii) is and has been
in compliance with applicable health care laws, including, the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.),
the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.),
the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), the
Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h), all criminal laws relating to health care fraud and abuse, including
but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the Health Insurance Portability
and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.) (“HIPAA”), the exclusion laws (42 U.S.C. §
1320a-7), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), HIPAA, as amended
by the Health Information Technology for Economic and Clinical Health Act of 2009, and the regulations promulgated pursuant to
such laws, and comparable state laws, and all other foreign, federal, state and local laws relating to the regulation of the Company
and its subsidiaries (collectively, “Health Care Laws”), (iii) has not engaged in activities which are, as applicable,
cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state
health care program or federal health care program, (iv) possesses all Permits and supplements or amendments thereto required by
any such Health Care Laws and/or to carry on its businesses as currently conducted as described in the Public Disclosure Documents
(“Authorizations”), and such Authorizations are valid and in full force and effect and neither the Company nor
any of its subsidiaries is in violation of any term of any such Authorizations, (v) has not received written notice of any ongoing
claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority
alleging that any product, operation or activity is in material violation of any Health Care Laws or Authorizations and has no
knowledge that any such Governmental Authority has threatened any such claim, litigation, arbitration, action, suit, investigation
or proceeding, (vi) has not received written notice that any Governmental Authority has taken, is taking or intends to take action
to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Authority has threatened
such action, (vii) has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments thereto as required by any Health Care Laws or Authorizations and all such reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete, correct and
not misleading on the date filed (or were corrected or supplemented by a subsequent submission), (viii) has not, either voluntarily
or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal
or replacement, safety alert, post sale warning, “dear doctor” letter, or other notice or action relating to the alleged
lack of safety, efficacy or regulatory compliance of any product or any alleged product defect or violation and, to the Company’s
knowledge, there are no facts which are reasonably likely to cause, and the Company has not received any written notice from the
FDA or any other Governmental Authority regarding, a material recall, market withdrawal or replacement of any Company product sold
or intended to be sold by the Company, a material change in the marketing classification or a material adverse change in the labeling
of any such Company products, or a termination or suspension of the manufacturing, marketing, or distribution of such Company products,
(ix) is not a party to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree,
settlement order, or similar agreements, or has any reporting obligations pursuant to any such agreement, plan or correction or
other remedial measure entered into with any Governmental Authority, (x) has not, nor has any officer, director, employee, agent
or, to the knowledge of the Company, any distributor of the Company, made an untrue statement of a material fact or a fraudulent
statement to the FDA or any other Governmental Authority, failed to disclose a material fact required to be disclosed to the FDA
or any other Governmental Authority, or committed an act, made a statement, or failed to make a statement, in each such case, related
to the business of the Company that, at the time such disclosure was made, would reasonably be expected to provide a basis for
the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”,
set forth in 56 Fed. Reg. 46191 (September 10, 1991) or for the FDA or any other Governmental Authority to invoke any similar policy,
(xi) has not, nor has any officer, director, employee, or, to the knowledge of the Company, any agent or distributor of the Company,
been debarred or convicted of any crime or engaged in any conduct for which debarment is mandated by 21 U.S.C. § 335a(a) or
any similar law or authorized by 21 U.S.C. § 335a(b) or any similar law applicable in other jurisdictions in which Company
products or Company product candidates are sold or intended by the Company to be sold, and (xii) neither the Company, its subsidiaries
nor their officers, directors, employees, agents or contractors has been or is currently debarred, suspended or excluded from participation
in the Medicare and Medicaid programs or any other state or federal health care program.

 

    	 	A-13	 

     

    

 

		4.40	The preclinical tests and clinical trials conducted or sponsored by, or on behalf of the Company
and its subsidiaries were and, if still pending, are being conducted in all material respects in accordance with protocols filed
with the appropriate regulatory authorities for each such test or trial, as the case may be, and with standard medical and scientific
research procedures and applicable laws, regulations and Authorizations, including without limitation, those of the FDA; each description
of the results of such tests and trials contained in the Public Disclosure Documents is accurate and complete in all material respects
and fairly presents the data derived from such tests and trials, and the Company and its subsidiaries have no knowledge of any
other studies or tests, the results of which are inconsistent with, or otherwise call into question, the results described or referred
to in the Public Disclosure Documents; and neither the Company nor any of its subsidiaries has received any notices or other correspondence
from the FDA, the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government
or drug or medical device regulatory agency requiring the termination, suspension or modification of any clinical trials..

 

		4.41	So long as any of the Notes or the Underlying Common Stock are outstanding, the Company will furnish
at its expense, upon request, to the holders of the Notes or the Underlying Common Stock and prospective purchasers of the Notes
or the Underlying Common Stock the information, if any, required by Rule 144A(d)(4) under the Securities Act.

 

		4.42	The Company and its affiliates will not take, directly or indirectly, any action designed to or
that has constituted or that reasonably could be expected to cause or result in the stabilization or manipulation of the price
of any security of the Company in connection with the sale of the Notes.

 

    	 	A-14	 

     

    

 

		4.43	The Company agrees not to sell, offer for sale or solicit offers to buy or otherwise negotiate
in respect of any “security” (as defined in the Securities Act) that would be integrated with the sale of the Notes
in a manner that would require the registration under the Securities Act of the sale of the Notes to the Investors. The Company
will take any reasonable precautions designed to insure that any offer or sale, direct or indirect of any Notes or any substantially
similar security issued by the Company, within six months subsequent to the date on which the distribution of the Notes has been
completed, is made under restrictions and other circumstances reasonably designed not to affect the status of the sale of the Notes
contemplated by this Agreement, as transactions exempt from the registration provisions of the Securities Act, including any sales
pursuant to Rule 144A under, or Regulation D of, the Securities Act.

 

		4.44	In connection with any offer or sale of the Notes, the Company will not engage, and will cause
its affiliates and any person acting on its behalf not to engage in any form of general solicitation or general advertising (within
the meaning of Regulation D of the Securities Act), or any “public offering” within the meaning of Section 4(a)(2)
of the Securities Act in connection with any sale of the Notes.

 

		4.45	The Company agrees to reserve and keep available at all times, free of preemptive rights, a sufficient
number of Underlying Common Stock to enable the Company to satisfy any obligations to issue Underlying Common Stock upon conversion
of the Notes.

 

		4.46	On and after the date hereof to, and including, the Closing Date, the Company will not do or authorize
any act that would result in an adjustment of the conversion rate of the Notes.

 

		5.	Representations, Warranties and Covenants of the Investors.

 

Each Investor hereby
represents and warrants to, and covenants with, the Company that:

 

		5.1	(1)	Each Investor is (a) either a QIB as defined in Rule 144A under the Securities Act, or an institutional
accredited investor as defined in Rule 501(a)(1), (a)(2), (a)(3), or (a)(7) under the Securities Act, as presently in effect, (b)
aware that the sale to it is being made in reliance on a private placement exemption from registration under the Securities Act,
and (c) acquiring the Securities for its own account or for the account of a QIB or an institutional accredited investor.

 

		(2)	Each Investor understands and agrees on behalf of itself and on behalf of any investor account
for which it is purchasing the Securities and Common Stock issuable upon conversion of the Securities, that the Securities and
Common Stock issuable upon conversion of the Securities are being offered in a transaction not involving any public offering within
the meaning of the Securities Act, that the Securities and Common Stock issuable upon conversion of the Securities have not been,
and will not be, registered under the Securities Act and that (a) if it decides to offer, resell, pledge or otherwise transfer
any of the Securities or Common Stock issued upon conversion of the Securities, such Securities and Common Stock may be offered,
resold, pledged or otherwise transferred only (i) to a person whom the seller reasonably believes is a QIB in a transaction meeting
the requirements of Rule 144A, (ii) pursuant to any other exemption from the registration requirements of the Securities Act, including
Rule 144 under the Securities Act (if available), (iii) pursuant to an effective registration statement under the Securities Act,
or (iv) to the Company, or one of its subsidiaries, in each of cases (i) through (iv) in accordance with any applicable securities
laws of any state of the United States.

 

    	 	A-15	 

     

    

 

		(3)	Each Investor understands that the Securities and Common Stock issued upon conversion of the Securities
will, unless sold pursuant to a registration statement that has been declared effective under the Securities Act or in compliance
with Rule 144, and will bear a legend that reflects the restricted nature of the securities.

 

		(4)	Each Investor:

 

		(a)	is able to fend for itself in the transactions contemplated hereby;

 

		(b)	has such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of its prospective investment in the Securities; and

 

		(c)	has the ability to bear the economic risks of its prospective investment and can afford the complete
loss of such investment.

 

		(5)	Each Investor acknowledges that (a) it has conducted its own investigation of the Company and the
terms of the Securities, (b) it has had access to, and has had an adequate opportunity to review, (i) all information the Company
has filed with and furnished to the Commission, (ii) all information set forth in such filings and (iii) such financial and other
information as it deems necessary to make its decision to purchase the Securities, and (c) it has been offered the opportunity
to ask questions of the Company, and received such answers thereto, as it deemed necessary in connection with the decision to purchase
the Securities.

 

		(6)	Each Investor understands that the Company, and others will rely upon the truth and accuracy of
the foregoing representations, acknowledgements and agreements and agrees that if any of the representations and acknowledgements
deemed to have been made by its purchase of the Securities are no longer accurate, such Investor shall promptly notify the Company.
If such Investor is acquiring the Securities as a fiduciary or agent for one or more investor accounts, it represents that it has
sole investment discretion with respect to each such account and it has full power to make the foregoing representations, acknowledgements
and agreements on behalf of such account.

 

    	 	A-16	 

     

    

 

		5.2	Each Investor acknowledges that no action has been or will be taken in any jurisdiction outside
the United States by the Company that would permit an offering of the Securities, or possession or distribution of offering materials
in connection with the issuance of the Securities (including any filing of a registration statement), in any jurisdiction outside
the United States where action for that purpose is required. Each Investor outside the United States will comply with all applicable
laws and regulations in each foreign jurisdiction in which it purchases, offers, sells or delivers Securities or has in its possession
or distributes any offering material, in all cases at its own expense.

 

		5.3	When the Securities are issued in accordance with the terms of this Agreement, all interest obligations
owed by the Company to such Investor on account of the Investor’s Notes will be current.

 

		5.4	Each Investor has full right, power, authority and capacity to enter into this Agreement and to
consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance
of this Agreement, and this Agreement constitutes a valid, binding and enforceable obligation of such Investor, except as the enforceability
of the Agreement may be subject to or limited by bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar
laws relating to or affecting the rights of creditors generally.

 

		5.5	The entry into and performance of this Agreement by each Investor and the consummation by such
Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents
of Investor, (ii) conflict with, or constitute a default under, or give to others any rights of termination, amendment, acceleration
or cancellation of any agreement, indenture or instrument to which such Investor is party, or (iii) result in the violation of
any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Investor,
except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually
or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Investor to perform its obligations
hereunder.

 

		5.6	Each Investor understands that nothing in this Agreement, information the Company has filed with
and furnished to the Commission or any other materials presented to such Investor in connection with the purchase and sale of the
Securities constitutes legal, tax or investment advice. Each Investor has consulted such legal, tax and investment advisors as
it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities and has made
its own assessment and has satisfied itself concerning the relevant tax and other economic considerations relevant to its investment
in the Securities.

 

    	 	A-17	 

     

    

 

		6.	Survival of Representations, Warranties and Agreements. Notwithstanding any investigation
made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company and the Investors
herein shall survive the execution of this Agreement, the delivery to the Investors of the Securities being purchased and the payment
therefor.

 

		7.	Notices. All notices, requests, consents and other communications hereunder shall be in
writing, shall be delivered (A) if within the domestic United States, by first-class registered or certified mail, or nationally
recognized overnight express courier, postage prepaid, or by facsimile, or (B) otherwise by International Federal Express or facsimile,
and shall be deemed given (i) if delivered by first-class registered or certified mail, three (3) business days after so mailed,
(ii) if delivered by a nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by International
Federal Express, two (2) business days after so mailed and (iv) if delivered by facsimile, upon electronic confirmation of receipt
and shall be delivered as addressed as follows:

 

if to the Company, to:

 

Xtant Medical Holdings, Inc.

600 Cruiser Lane

Belgrade, Montana 59714

Attention: President

 

if to the Investors, at each
Investor’s address on the signature page hereto, or at such other address or addresses as may have been furnished to the
Company in writing.

 

		8.	Changes. Except as contemplated herein, this Agreement may not be modified or amended except
pursuant to an instrument in writing signed by the Company and each Investor.

 

		9.	Headings. The headings of the various sections of this Agreement have been inserted for
convenience or reference only and shall not be deemed to be part of this Agreement.

 

		10.	Severability. In case any provision contained in this Agreement should be invalid, illegal
or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not
in any way be affected or impaired thereby.

 

		11.	Applicable Law; Venue. This Agreement will be governed by and construed in accordance with
the laws of the State of New York applicable to contracts made and to be performed within the State of New York. Each of the Company
and each Investor agrees that any suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated
hereby may be instituted only in any State or U.S. federal court in The City of New York and County of New York and waives
any objection that such party may now or hereafter have to the laying of venue of any such suit, action or proceeding, and irrevocably
submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding.

 

    	 	A-18	 

     

    

 

		12.	Waiver of Jury Trial. Each of the Company and each Investor hereby irrevocably waives, to
the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating
to this Agreement or the transactions contemplated hereby.

 

		13.	Counterparts. This Agreement may be signed in one or more counterparts, each of which
shall constitute an original and all of which together shall constitute one and the same agreement.

 

		14.	Payment of Expenses. The Company agrees to pay on demand all expenses of the Investors incurred
in connection with the Investors’ review, consideration and evaluation of this Agreement, the Securities and the Registration
Rights Agreement, including the rights and remedies available to it in connection therewith, and the negotiation, preparation,
execution and delivery of this Agreement, the Securities and the Registration Rights Agreement.

 

    	 	A-19	 

     

    

 

Exhibit A

 

Form of Convertible
Promissory Note

 

[See Attached.]

 

    	 	Ex A-1EXHIBIT 10.11

 

THE SALE OF THIS NOTE HAS NOT BEEN REGISTERED
UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS NOTE (AND ANY BENEFICIAL
INTEREST HEREIN) MAY NOT BE OFFERED, RESOLD OR OTHERWISE TRANSFERRED, EXCEPT:

 

(A)         TO
THE COMPANY OR ANY SUBSIDIARY THEREOF;

 

(B)         PURSUANT
TO A REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT; OR

 

(C)         UNDER
ANY AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT (INCLUDING, IF AVAILABLE, THE EXEMPTION PROVIDED
BY RULE 144 UNDER THE SECURITIES ACT).

 

PRIOR TO ANY TRANSFER PURSUANT TO THE
FOREGOING CLAUSE (C), THE COMPANY RESERVES THE RIGHT TO REQUIRE THE DELIVERY OF SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION
AS THE COMPANY MAY REASONABLY REQUIRE AND MAY RELY UPON TO CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE SECURITIES LAWS OF ANY OTHER
JURISDICTION. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT.

 

XTANT MEDICAL HOLDINGS, INC.

 

CONVERTIBLE PROMISSORY NOTE

 

	$42,856.59	Date of Issuance: January 17, 2017

 

FOR VALUE RECEIVED, Xtant Medical Holdings,
Inc., a Delaware corporation (the “Company”), promises to pay to ROS Acquisition Offshore LP, and its assigns,
(the “Holder”) the principal sum of $42,856.59 (the “Principal Amount”), in the manner provided
herein. Commencing on the date hereof, and continuing until such time as the Principal Amount is repaid in full, interest shall
accrue on the Principal Amount outstanding at the rate of six percent (6.00%) per annum. This Note is one of a series of notes
of the Company issued on the date hereof (the “Series”). This Note is subject to the following terms and conditions.

  

    	 	- 1 -	 

     

    

 

TABLE OF CONTENTS

 

	 	 	 	Page
	 	 	 	 
	Article 1	DEFINITIONS AND INCORPORATION BY REFERENCE	4
	 	 	 	 
	Section 1.01	Definitions	4
	Section 1.02	Other Definitions	8
	Section 1.03	Rules of Construction	8
	 	 	 	 
	Article 2	PAYMENT TERMS, TRANSFER RESTRICTIONS AND NOTE REPLACEMENT	9
	 	 	 	 
	Section 2.01	Payments	9
	Section 2.02	Replacement Note	10
	 	 	 	 
	Article 3	REPURCHASE AT THE OPTION OF THE HOLDER	11
	 	 	 	 
	Section 3.01	Fundamental Change Permits Holder to Require the Company to Repurchase this Note	11
	Section 3.02	Fundamental Change Notice	11
	Section 3.03	Fundamental Change Repurchase Notice	13
	Section 3.04	Withdrawal of Fundamental Change Repurchase Notice	13
	Section 3.05	Effect of Fundamental Change Repurchase Notice	14
	Section 3.06	Note Repurchased in Part	14
	Section 3.07	Covenant to Comply With Securities Laws Upon Repurchase of Note	14
	 	 	 	 
	Article 4	COVENANTS	15
	 	 	 	 
	Section 4.01	Payment of Note.	15
	Section 4.02	144A Information	15
	Section 4.03	Reports	15
	Section 4.04	Additional Interest	15
	Section 4.05	Compliance Certificate	16
	Section 4.06	Corporate Existence	16
	Section 4.07	Par Value Limitation.	16
	Section 4.08	Stay, Extension and Usury Laws	17
	Section 4.09	Further Instruments and Acts	17
	 	 	 	 
	Article 5	CONSOLIDATION, MERGER AND SALE OF ASSETS	17
	 	 	 	 
	Section 5.01	Company May Consolidate, Merge or Sell Its Assets Only on Certain Terms	17
	Section 5.02	Successor Substituted	18
	 	 	 	 
	Article 6	DEFAULTS AND REMEDIES	18
	 	 	 	 
	Section 6.01	Events of Default	18

 

    	 	- 2 -	 

     

    

 

	Section 6.02	Acceleration	20
	Section 6.03	Other Remedies	20
	Section 6.04	Sole Remedy for Failure to Report	21
	Section 6.05	Waiver of Past Defaults	22
	 	 	 	 
	Article 7	SATISFACTION AND DISCHARGE	22
	 	 	 	 
	Section 7.01	Discharge of Liability on Note	22
	 	 	 	 
	Article 8	CONVERSIONS	22
	 	 	 	 
	Section 8.01	Right To Convert	22
	Section 8.02	Conversion Procedures	23
	Section 8.03	Settlement Upon Conversion	24
	Section 8.04	Common Stock Issued Upon Conversion	25
	Section 8.05	Adjustment of Conversion Rate	25
	Section 8.06	Voluntary Adjustments	34
	Section 8.07	Adjustments Upon Certain Fundamental Changes	34
	Section 8.08	Effect of Recapitalization, Reclassification, Consolidation, Merger or Sale	36
	 	 	 	 
	Article 9	NO RIGHT OF REDEMPTION AT THE OPTION OF THE COMPANY	38
	 	 	 	 
	Article 10	MISCELLANEOUS	38
	 	 	 	 
	Section 10.01	Notices	38
	Section 10.02	Separability Clause	39
	Section 10.03	Governing Law and Waiver of Jury Trial	39
	Section 10.04	No Recourse Against Others	39
	Section 10.05	Calculations	39
	Section 10.06	Successors	39
	Section 10.07	Table of Contents; Headings	39
	Section 10.08	Submission to Jurisdiction	39
	Section 10.09	Legal Holidays	40
	Section 10.10	No Security Interest Created	40
	Section 10.11	Benefits of Note	40
	Section 10.12	Withholding Taxes	40
	Section 10.13	Amendment and Waiver	40

 

    	 	- 3 -	 

     

    

 

Article
1

DEFINITIONS AND INCORPORATION BY REFERENCE

 

Section
1.01         Definitions.

 

“Additional
Interest” has the meaning ascribed to it in the Registration Rights Agreement.

 

“Affiliate”
of any specified Person means any other Person, directly or indirectly, controlling or controlled by or under direct or indirect
common control with such specified Person. For the purposes of this definition, “control,” when used with respect
to any specified Person, means the power to direct or cause the direction of the management and policies of such Person, directly
or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling”
and “controlled” have meanings correlative to the foregoing.

 

“Bankruptcy
Law” means Title 11, United States Code, or any similar U.S. federal, state or non-U.S. law for the relief of debtors.

 

“Board of
Directors” means the board of directors of the Company or a committee of such board duly authorized to act for it.

 

“Business
Day” means any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York is authorized
or required by law or executive order to close or be closed.

 

“Capital Stock”
means, for any Person, any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents
of, or interests in (however designated), the equity of such Person, but excluding any debt securities convertible into such equity.

 

“Close of
Business” means 5:00 p.m., New York City time.

 

“Common Stock”
means the shares of the common stock of the Company, $0.000001 par value per share.

 

“Company”
means the party named as such in the first paragraph of this Note until a successor or assignee replaces it pursuant to the applicable
provisions hereof and, thereafter, means the successor or assignee.

 

“Conversion
Price” means, at any time, (i) $1,000 divided by (ii) the Conversion Rate in effect at such time.

 

“Conversion
Rate” means, initially, 1,317.70 shares of Common Stock per $1,000 principal amount of this Note, subject to adjustment
as provided herein, or in the case of a principal amount or portion of a principal amount that is not a multiple of $1,000, an
equivalent pro rata number of shares.

 

    	 	- 4 -	 

     

    

 

“Custodian”
means any receiver, trustee, assignee, liquidator, custodian or similar official under any Bankruptcy Law.

 

“Default”
means any event which is (or after notice, passage of time or both would be) an Event of Default.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Fundamental
Change” means an event that will be deemed to occur if any of the following occurs:

 

(a)          a
“person” or “group” within the meaning of Section 13(d) of the Exchange Act, other than the Company or
the Subsidiaries, has become the direct or indirect “beneficial owner” (as defined below) of shares of the Company’s
common equity representing more than 50% of the voting power of the Company’s common equity;

 

(b)          the
consummation of:

 

(i)          any
sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets
of the Company and the Subsidiaries to any person; or

 

(ii)         any
transaction or series of related transactions in connection with which (whether by means of exchange, liquidation, consolidation,
merger, combination, reclassification, recapitalization, acquisition or otherwise) all of the Common Stock is exchanged for, converted
into, acquired for, or constitutes solely the right to receive, other securities, other property, assets or cash, but excluding
any merger, consolidation, share exchange or acquisition of the Company with or by another Person pursuant to which the Persons
that “beneficially owned” (as defined below), directly or indirectly, the shares of the Company’s Voting Stock
immediately prior to such transaction beneficially own, directly or indirectly, immediately after such transaction, shares of the
surviving, continuing or acquiring corporation’s Voting Stock representing more than 50% of the total outstanding voting
power of all outstanding classes of Voting Stock of the surviving, continuing or acquiring corporation in substantially the same
proportions vis-à-vis each other as immediately prior to such transaction; or

 

(c)          the
Company’s stockholders approve any plan or proposal for the liquidation or dissolution of the Company.

 

A transaction or event described in clause
(a) or (b) above will not constitute a Fundamental Change, however, if at least 90% of the consideration received or to be received
by the holders of the Common Stock, excluding cash payments for fractional shares or dissenters rights, in connection with the
transaction or transactions, consists of shares of common stock traded on any of the NASDAQ Capital Market, the NASDAQ Global Market,
the NASDAQ Global Select Market, the NYSE MKT LLC or the New York Stock Exchange (or any of their respective successors) or which
will be so traded or quoted when issued or exchanged in connection with such transaction or event and as a result of such transaction
or event, this Note become convertible or exchangeable solely into such consideration (excluding cash payable in lieu of any fractional
share) in accordance with Section 8.08.

 

    	 	- 5 -	 

     

    

 

For the purposes of
this definition of “Fundamental Change,” whether a person is a “beneficial owner” or whether shares
are “beneficially owned” will be determined in accordance with Rule 13d-3 under the Exchange Act.

 

“Holder”
means the party named as such in the first paragraph of this Note.

 

“Issue Date”
means January 17, 2017.

 

“Last Reported
Sale Price” of the Common Stock on any date means the closing sale or trading price (or, if no closing sale or trading
price is reported, the average of the last bid and last ask prices or, if more than one in either case, the average of the average
last bid and the average last ask prices) per share on such date as reported in composite transactions for the principal U.S. national
or regional securities exchange on which the Common Stock is traded. If the Common Stock is not listed for trading on a U.S. national
or regional securities exchange on such date, the “Last Reported Sale Price” of the Common Stock will be the last quoted
bid price per share for the Common Stock in the over-the-counter market on such date as reported by OTC Markets Group Inc. or a
similar organization. If the Common Stock is not so quoted, the “Last Reported Sale Price” will be the average of the
mid-point of the last bid and last ask prices per share for the Common Stock on the relevant date from each of at least three (3)
nationally recognized independent investment banking firms selected by the Company for this purpose. The “Last Reported Sale
Price” will be determined without regard to after-hours trading or any other trading outside of regular trading session hours.

 

“Market Disruption
Event” means the occurrence or existence during the one-half hour period ending on the scheduled close of trading on
the principal U.S. national or regional securities exchange or other market on which the Common Stock is listed for trading or
trades of any material suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted
by the stock exchange or otherwise) in the Common Stock or in any options contracts or futures contracts relating to the Common
Stock.

 

“Officer”
means the Chairman of the Board, the Vice Chairman, the Chief Executive Officer, the President, the Chief Financial Officer, any
Executive Vice President, any Senior Vice President, any Vice President, the Treasurer or the Secretary of the Company.

 

“Officers’
Certificate” means a written certificate containing the information specified in Sections 4.05, 5.01(c),
signed in the name of the Company by any two Officers, and delivered to the Holder; provided, that, if such certificate
is given pursuant to Section 4.05, one of the Officers signing such certificate must be the Chief Financial Officer of the
Company.

 

“Open of Business”
means 9:00 a.m., New York City time.

 

“Opinion of
Counsel” means a written opinion containing the information specified in Section 5.01(c), from legal counsel satisfactory
to holders of a majority of the Series. The counsel may be an employee of, or counsel to, the Company who is satisfactory to holders
of a majority of the Series.

 

    	 	- 6 -	 

     

    

 

“Person”
means any individual, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust,
unincorporated organization, or government or any agency or political subdivision thereof.

 

“Registration
Rights Agreement” means the Registration Rights Agreement, dated as of the date hereof, among the Company and the holders
of the notes of the Series.

 

“Rule 144”
means Rule 144 under the Securities Act (or any successor provision), as it may be amended from time to time.

 

“Rule 144A”
means Rule 144A under the Securities Act (or any successor provision), as it may be amended from time to time.

 

“SEC”
means the Securities and Exchange Commission.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Significant
Subsidiary” means any Subsidiary that is a “significant subsidiary” of the Company within the meaning of
Rule 1-02(w) of Regulation S-X promulgated under the Exchange Act.

 

“Stock Price”
means, for any Make-Whole Fundamental Change, (i) if the holders of the Common Stock receive only cash in consideration for their
shares of Common Stock in such Make-Whole Fundamental Change and such Make-Whole Fundamental Change is of the type described in
clause (b) of the definition of Fundamental Change, the amount of cash paid per share of the Common Stock in such Make-Whole Fundamental
Change; and (ii) otherwise, the average of the Last Reported Sale Price per share of the Common Stock over the five consecutive
Trading Days ending on, and including, the Trading Day immediately preceding the Make-Whole Fundamental Change Effective Date for
such Make-Whole Fundamental Change.

 

“Subsidiary”
means a Person more than 50% of the outstanding Voting Stock of which is owned, directly or indirectly, by the Company or by one
or more other Subsidiaries of the Company, or by the Company and one or more other Subsidiaries of the Company.

 

“Trading Day”
means a day on which (i) trading in the Common Stock (or other security for which a Last Reported Sale Price must be determined)
generally occurs on the NYSE MKT or, if the Common Stock (or such other security) is not then listed on the NYSE MKT, on the principal
other U.S. national or regional securities exchange on which the Common Stock (or such other security) is then listed or, if the
Common Stock (or such other security) is not then listed on a U.S. national or regional securities exchange, on the principal other
market (including, without limitation, the OTCQX marketplace) on which the Common Stock (or such other security) is then listed
or admitted for trading; and (ii) there is no Market Disruption Event; provided, however, that if the Common Stock
(or such other security) is not so listed or traded, then “Trading Day” means a Business Day.

 

“Uniform Commercial
Code” means the New York Uniform Commercial Code as in effect on the Issue Date.

 

    	 	- 7 -	 

     

    

 

“Voting Stock”
of a Person means Capital Stock of such Person of the class or classes pursuant to which the holders thereof have the general voting
power under ordinary circumstances to elect at least a majority of the board of directors, managers or trustees of such Person
(irrespective of whether or not at the time Capital Stock of any other class or classes will have or might have voting power by
reason of the happening of any contingency).

 

Section
1.02         Other Definitions.

 

	Term:	 	Section
    Defined in:
	“Additional Shares”	 	8.07(a)
	“Averaging Period”	 	8.05(e)
	“Common Stock Change Event”	 	8.08
	“Conversion Consideration”	 	8.03(a)(i)
	“Conversion Date”	 	8.02(a)
	“Conversion Notice”	 	8.02(a)
	“Defaulted Amount”	 	2.01(b)
	“Default Interest”	 	2.01(b)
	“Effective Date”	 	8.05(l)(i)(III)
	“Event of Default”	 	6.01(a)
	“Ex-Dividend Date”	 	8.05(l)(i)(IV)
	“Expiration Date”	 	8.05(e)
	“Expiration Time”	 	8.05(e)
	“Fundamental Change Notice”	 	3.02(a)
	“Fundamental Change Notice
    Date”	 	3.02(a)
	“Fundamental Change Repurchase
    Date”	 	3.01(c)
	“Fundamental Change Repurchase
    Notice”	 	3.03(a)(i)
	“Fundamental Change Repurchase
    Price”	 	3.01(b)
	“Interest Payment Date”	 	2.01(a)(ii)
	“Make-Whole Fundamental Change”	 	8.07(a)
	“Make-Whole Fundamental Change
    Effective Date”	 	8.07(b)
	“Maturity Date”	 	2.01(a)(i)
	“Principal Amount”	 	Introductory Paragraph
	“Reference Property”	 	8.08(a)
	“Reference Property Unit”	 	8.08(a)
	“Regular Record Date”	 	2.01(a)(ii)
	“Reorganization Event”	 	5.01
	“Reorganization Successor Corporation”	 	5.01(a)(ii)
	“Reporting Event of Default”	 	6.04(a)
	“Series”	 	Introductory Paragraph
	“Special Interest”	 	6.04(a)
	“Spin-Off”	 	8.05(c)(ii)
	“Valuation Period”	 	8.05(c)(ii)

 

Section
1.03         Rules of Construction. In this Note:

 

(a)          a
term has the meaning assigned to it;

 

    	 	- 8 -	 

     

    

 

(b)          an
accounting term not otherwise defined has the meaning assigned to it and will be construed in accordance with U.S. generally accepted
accounting principles;

 

(c)          “or”
is not exclusive;

 

(d)          “including”
means including, without limitation;

 

(e)          words
in the singular include the plural, and words in the plural include the singular, unless the context requires otherwise;

 

(f)          “herein,”
“hereof” and other words of similar import refer to this Note as a whole and not to any particular
Article, Section or other subdivision of this Note, unless the context requires otherwise;

 

(g)          all
references to $, dollars, cash payments or money refer to United States currency; and

 

(h)          unless
the context requires otherwise, all references to interest on this Note will (i) include any Additional Interest payable pursuant
to the Registration Rights Agreement and any Special Interest payable pursuant to Section 6.04; and (ii) for the avoidance
of doubt, not include any Default Interest payable on a Defaulted Amount pursuant to Article 2.

 

Article
2

PAYMENT TERMS, TRANSFER RESTRICTIONS AND NOTE REPLACEMENT

 

Section
2.01         Payments.

 

(a)          General.

 

(i)          Payment
at Maturity. Unless earlier paid or deemed paid pursuant to any of Sections 3.05 or 8.03, this Note will mature
on July 15, 2021 (the “Maturity Date”) and, on the Maturity Date, the Company will pay the Holder $1,000 in
cash for each $1,000 principal amount of this Note (and in the case of a principal amount or portion of a principal amount that
is not a multiple of $1,000, an equivalent pro rata amount), together with accrued and unpaid interest to, but not including, the
Maturity Date (with such interest to be payable to the Holder as of the Close of Business on the Regular Record Date immediately
preceding the Maturity Date).

 

(ii)         Payment
of Interest. This Note will accrue interest at a rate equal to 6.00% per annum from the most recent date to which interest
has been paid or duly provided for, or, if no interest has been paid or duly provided for, the Issue Date until, subject to Section
2.01(b), the date the principal amount of this Note is paid or deemed to be paid, as the case may be, pursuant to clause (i)
of this Section 2.01(a) or any of Sections 3.05 or 8.03. Additional Interest will accrue on this Note
to the extent provided in the Registration Rights Agreement and Special Interest will accrue on this Note to the extent provided
in Section 6.04, in each case in addition to interest accruing on this Note pursuant to the immediately preceding sentence.
Except as otherwise provided herein (including Section 3.01(b) and Section 8.02(d)), interest will be payable semi-annually
in arrears on January 15 and July 15 of each year (each, an “Interest Payment Date”) to the Holder as of the
Close of Business on the January 1 or July 1, as the case may be, and whether or not on a Business Day, immediately preceding the
applicable Interest Payment Date (each such date, a “Regular Record Date”). Interest on this Note that has been
converted or repurchased after a Regular Record Date and on or before the related Interest Payment Date will be paid in the manner
set forth in Section 3.01(b) and Section 8.02(d), as applicable. Interest will be computed on the basis of a 360-day
year comprised of twelve 30-day months.

 

    	 	- 9 -	 

     

    

 

(iii)        Method
of Payment. The Company will pay the principal of and the Fundamental Change Repurchase Price for this Note by check or wire
transfer, in the manner set forth below, to the Holder on the relevant payment date upon surrender thereof to the Company and,
if applicable, satisfaction of any other requirements therefor set forth in Article 3. The Company will pay interest due,
on an Interest Payment Date, on (and, subject to the immediately preceding sentence, the principal of or the Fundamental Change
Repurchase Price for) this Note to the Holder (i) by check mailed to the Holder’s registered address; or (ii) if the Holder
delivers, not later than the Regular Record Date relating to such Interest Payment Date (or, with respect to the payment of the
principal of or the Fundamental Change Repurchase Price for such Note, the date that is fifteen (15) days immediately preceding
the Maturity Date or related Fundamental Change Repurchase Date, as applicable), a written request to the Company that the Company
make such payments by wire transfer to an account of the Holder within the United States, by wire transfer of immediately available
funds to such account, which request shall remain in effect until the Holder notifies the Company, in writing, to the contrary.

 

(b)          Defaulted
Amounts. Whenever any amount payable on this Note (including, the principal of, the Fundamental Change Repurchase Price for,
and interest on, this Note) has become due and payable, but the Company fails to punctually pay or to duly provide for such amount
(any such amount, a “Defaulted Amount”), in each case regardless of whether such failure constitutes an Event
of Default, then such Defaulted Amount will accrue interest (“Default Interest”) at a rate equal to 6.00% per
annum plus 100 basis points from, and including, such payment date and to, but excluding, the date on which such Defaulted Amount
is paid by the Company, which Default Interest shall be payable by the Company on demand.

 

(c)          Acknowledgement
and Agreement by the Holder. The Holder, by accepting this Note, acknowledges and agrees to comply with the restrictions set
forth in this Note’s legend.

 

Section 2.02         Replacement
Note.  If (a)(i) this Note is mutilated and surrendered to the Company; or (ii) the Holder claims that this Note has been
lost, destroyed or stolen and provides the Company with (A) evidence of such loss, theft or destruction that is reasonably satisfactory
to the Company; and (B) any amount or kind of security or indemnity that the Company requests to protect itself from any loss
that it may suffer upon replacement of this Note; and, in either case, (b) such Holder satisfies any other reasonable requirements
of the Company, including the payment of any tax or other governmental charge that may be imposed in connection with the replacement
of this Note, then, unless the Company receives notice that this Note has been acquired by a bona fide purchaser, the Company
will promptly execute and deliver to the Holder a replacement Note having the same aggregate principal amount as this Note that
was mutilated or claimed to be lost, destroyed or stolen.

 

    	 	- 10 -	 

     

    

 

Every new Note issued pursuant to this
Section 2.02 in exchange for a mutilated Note, or in lieu of a destroyed, lost or stolen Note, will constitute an original
contractual obligation of the Company and any other obligor upon this Note, regardless of whether the mutilated, destroyed, lost
or stolen Note will be at any time enforceable by anyone, and will be entitled to all of the benefits, and subject to all the limitations,
set forth herein.

 

Article
3

REPURCHASE AT THE OPTION OF THE HOLDER

 

Section
3.01         Fundamental Change Permits Holder to Require the Company to Repurchase
this Note.

 

(a)          General.
If a Fundamental Change occurs at any time prior to the Maturity Date, the Holder will have the right, at its option, to require
the Company to repurchase this Note, or any portion thereof, on the Fundamental Change Repurchase Date for such Fundamental Change
for an amount of cash equal to the Fundamental Change Repurchase Price for such Fundamental Change Repurchase Date and this Note.

 

(b)          Fundamental
Change Repurchase Price. The “Fundamental Change Repurchase Price” means, for this Note to be repurchased
on any Fundamental Change Repurchase Date, a price equal to 100% of the principal amount of this Note, plus accrued and unpaid
interest, if any, on this Note to, but excluding, such Fundamental Change Repurchase Date; provided, however, that
if such Fundamental Change Repurchase Date occurs after a Regular Record Date, but on or prior to the Interest Payment Date corresponding
to such Regular Record Date, the Fundamental Change Repurchase Price for this Note will be 100% of the principal amount of this
Note, and accrued and unpaid interest, if any, on this Note to, but excluding, such Interest Payment Date (assuming, solely for
these purposes, that this Note remained outstanding through such Interest Payment Date) will be payable, on such Fundamental Change
Repurchase Date, to the Holder as of the Close of Business on such Regular Record Date.

 

(c)          Fundamental
Change Repurchase Date. The “Fundamental Change Repurchase Date” means, for any Fundamental Change, the
date specified by the Company in the Fundamental Change Notice for such Fundamental Change, which date will be not less than twenty
(20) Business Days, nor more than thirty five (35) Business Days, immediately following the Fundamental Change Notice Date for
such Fundamental Change.

 

Section 3.02         Fundamental
Change Notice.

 

(a)          General.
On or before the Business Day immediately following the effective date of a Fundamental Change, the Company will deliver to the
Holder written notice of such Fundamental Change and of the resulting repurchase right (the “Fundamental Change Notice”,
and the date of such delivery, the “Fundamental Change Notice Date”).

 

    	 	- 11 -	 

     

    

 

The Fundamental Change Notice for each
Fundamental Change will specify, as applicable:

 

(A)         briefly,
the events causing such Fundamental Change;

 

(B)         the
effective date of such Fundamental Change;

 

(C)         the
last date on which the Holder may exercise its right to require the Company to repurchase this Note as a result of such Fundamental
Change under this Article 3;

 

(D)         the
procedures that the Holder must follow to require the Company to repurchase this Note;

 

(E)          the
Fundamental Change Repurchase Price for each $1,000 principal amount this Note for such Fundamental Change (and in the case of
a principal amount or portion of a principal amount that is not a multiple of $1,000, the equivalent pro rata amount);

 

(F)         the
Fundamental Change Repurchase Date for such Fundamental Change;

 

(G)         in
the event that a Fundamental Change Repurchase Notice has been duly tendered in respect of this Note and not validly withdrawn,
the Fundamental Change Repurchase Price which will be paid promptly following the later of the Fundamental Change Repurchase Date
and the time this Note is surrendered for repurchase;

 

(H)         the
Conversion Rate in effect on the Fundamental Change Notice Date for such Fundamental Change and the Last Reported Sale Price of
the Common Stock on the Trading Day immediately preceding the Fundamental Change Notice Date;

 

(I)          if
applicable, any adjustments that will be made to the Conversion Rate as a result of such Fundamental Change, including any Additional
Shares by which the Conversion Rate will be increased pursuant to Section 8.07 in the event that the Holder converts this
Note “in connection with” such Fundamental Change;

 

(J)          that
in the event that a Fundamental Change Repurchase Notice has been delivered by the Holder, this Note may be converted only if the
Holder withdraws such Fundamental Change Repurchase Notice in accordance with the terms of this Note or to the extent any portion
of this Note are not subject to such Fundamental Change Repurchase Notice;

 

(K)         the
procedures for withdrawing a Fundamental Change Repurchase Notice;

 

    	 	- 12 -	 

     

    

 

(L)         that
if this Note or portion of this Note is subject to a validly delivered Fundamental Change Repurchase Notice, unless the Company
defaults in paying the Fundamental Change Repurchase Price for this Note or portion of this Note, interest, if any, on this Note
or portion of this Note will cease to accrue on and after the Fundamental Change Repurchase Date; and

 

(b)          Failure
or Defect. Notwithstanding anything provided elsewhere in this Note, neither the failure of the Company to deliver a Fundamental
Change Notice nor a defect in a Fundamental Change Notice delivered by the Company will limit the repurchase rights of the Holder
under this Article 3 or impair or otherwise affect the validity of any proceedings relating to the repurchase of this Note
pursuant to this Article 3.

 

Section
3.03         Fundamental Change Repurchase Notice.

 

(a)          General.
To exercise its repurchase rights under Section 3.01(a) with respect to this Note pursuant to a Fundamental Change, the
Holder must:

 

(i)          deliver
to the Company, by the Close of Business on the second (2nd) Business Day immediately preceding the Fundamental Change Repurchase
Date, subject to extension to comply with applicable law, a duly completed Fundamental Change Repurchase notice, substantially
in the form set forth in Exhibit B hereto (a “Fundamental Change Repurchase Notice”) setting forth that
the Holder is tendering this Note for repurchase; and

 

(ii)         deliver
this Note to the Company by physical delivery together with any endorsements or other documents reasonably requested by the Company.

 

(b)          Contents
of Fundamental Change Repurchase Notice. The Fundamental Change Repurchase Notice for this Note must state:

 

(i)          if
this Note is to be repurchased in part, the portion of the principal amount of this Note to be repurchased; and

 

(ii)         that
this Note will be repurchased by the Company pursuant to the provisions of this Article 3.

 

(c)          Effect
of Improper Notice. Unless and until the Company receives a validly delivered Fundamental Change Repurchase Notice with respect
to this Note, together with this Note, in a form that conforms in all material aspects with the description contained in such Fundamental
Change Repurchase Notice, the Holder will not be entitled to receive the Fundamental Change Repurchase Price for this Note.

 

Section 3.04         Withdrawal
of Fundamental Change Repurchase Notice.

 

(a)          General.
After the Holder delivers a Fundamental Change Repurchase Notice with respect to this Note, the Holder may withdraw such Fundamental
Change Repurchase Notice (in whole or in part) with respect to this Note or any portion of this Note by delivering to the Company
a written notice of withdrawal prior to the Close of Business on the second (2nd) Business Day immediately preceding the Fundamental
Change Repurchase Date. Any such withdrawal notice must state the principal amount of this Note, if any, that remains subject to
the Fundamental Change Repurchase Notice.

 

    	 	- 13 -	 

     

    

 

(b)          Return
of Note. Upon receipt of a validly delivered withdrawal notice, the Company will promptly return this Note or portion of this
Note to the Holder, in the amount specified in such withdrawal notice.

 

Section
3.05         Effect of Fundamental Change Repurchase Notice.

 

(a)          General.
If the Holder validly delivers to the Company a Fundamental Change Repurchase Notice (together with all necessary endorsements)
with respect to this Note, the Holder may no longer convert this Note unless and until the Holder validly withdraws such Fundamental
Change Repurchase Notice in accordance with Section 3.04.

 

(b)          Timing
of Payment. Upon the Company’s receipt of (i) a valid Fundamental Change Repurchase Notice (together with all necessary
endorsements); and (ii) this Note to which such Fundamental Change Repurchase Notice pertains, the Holder will be entitled, except
to the extent the Holder has validly withdrawn such Fundamental Change Repurchase Notice in accordance with Section 3.04,
to receive the Fundamental Change Repurchase Price with respect to this Note on the later of the following (subject to extension
to comply with applicable law): (x) the Fundamental Change Repurchase Date; and (y) the date of delivery of this Note to the Company,
duly endorsed.

 

(c)          Effect
of Payment. Upon receipt by the Holder of the Fundamental Change Repurchase Price:

 

(A)         this
Note will cease to be outstanding and interest (except Default Interest) will cease to accrue on this Note, except to the extent
provided in the proviso to Section 3.01(b); and

 

(B)         all
other rights of the Holder with respect to this Note (other than the right to receive payment of the Fundamental Change Repurchase
Price upon delivery or transfer of this Note and any Defaulted Amounts or Default Interest with respect to this Note, and other
than as provided in the proviso to Section 3.01(b)) will terminate.

 

Section
3.06         Note Repurchased in Part. If this Note is to be repurchased only
in part, the Holder must surrender this Note to the Company, whereupon the Company will promptly deliver to the Holder a new Note
of any denomination or denominations equal to the portion of the principal amount of this Note so surrendered which is not repurchased.

 

Section 3.07         Covenant
to Comply With Securities Laws Upon Repurchase of Note. In connection with any repurchase offer pursuant to a Fundamental
Change Repurchase Notice under this Article 3, the Company will comply with any applicable United States federal and state
securities laws so as to permit the Holder to exercise its rights and obligations under this Article 3 in the time and
in the manner specified in Sections 3.01 and 3.03.

 

    	 	- 14 -	 

     

    

 

Article
4

COVENANTS

 

Section
4.01         Payment of Note. The Company will pay or cause to be paid
the principal of, Fundamental Change Repurchase Price for, and any accrued and unpaid interest (including, for the avoidance
of doubt, any Additional Interest or Special Interest) on, this Note on the dates and in the manner required under this Note.
To the extent lawful, the Company will also pay Default Interest on any Defaulted Amounts in accordance with Section
2.01.

 

Section
4.02         144A Information Whenever the Company is not subject to
Section 13 or Section 15(d) of the Exchange Act, if this Note or shares of Common Stock, if any, issuable upon the conversion
of this Note constitute “restricted securities” within the meaning of Rule 144, the Company will, upon the
request of the Holder or beneficial owner of this Note, or a holder or beneficial owner of the Common Stock, if any, issuable
upon the conversion of this Note, (i) promptly furnish or cause to be furnished to the applicable Holder, beneficial owner,
or any prospective purchaser designated by the applicable Holder or beneficial owner, of this Note, or any holder, beneficial
owner, or any prospective purchaser designated by the applicable holder or beneficial owner, of the Common Stock, as
applicable, all of the information that a prospective purchaser of this Note or the Common Stock, as applicable, is required
to receive under Rule 144A(d)(4) of the Securities Act for this Note or shares of Common Stock, as applicable, to be resold
to such prospective purchaser pursuant to the exemption from registration provided by Rule 144A and (ii) make publicly
available such information as necessary to permit sales pursuant to Rule 144, as the case may be.

 

Section
4.03         Reports. The Company will deliver to the Holder copies of all
quarterly and annual reports that the Company is required to deliver to the SEC on Forms 10-Q and 10-K, respectively, and any
other documents, information or other reports that the Company is required to file with the SEC under Sections 13 or 15(d) of
the Exchange Act no later than the date that the Company is required to file such quarterly and annual reports, other documents,
information or other reports with the SEC (after giving effect to any grace period provided by Rule 12b-25 under the Exchange
Act). Any document filed by the Company with the SEC via the EDGAR system (or any successor thereto) will be deemed to be delivered
to the Holder at the time such document is filed via the EDGAR system (or such successor). Notwithstanding anything to the contrary
in the foregoing, nothing in this paragraph shall require the Company to deliver to any Holder any material for which the Company
has sought and received, or is seeking and has not been denied, confidential treatment by the SEC.

 

Section
4.04         Additional Interest.

 

(a)          General.
Additional Interest will accrue on this Note to the extent provided in the Registration Rights Agreement, and the Company’s
obligation to pay any such Additional Interest will be deemed to be obligations under this Note with the same force and effect
as if the relevant provisions of the Registration Rights Agreement were reproduced in this Note.

 

    	 	- 15 -	 

     

    

 

Section
4.05         Compliance Certificate.

 

(a)          Annual
Compliance Certificate. Within ninety (90) days after the end of each fiscal year of the Company, beginning with the fiscal
year ending on December 31, 2017, the Company will deliver to the Holder an Officers’ Certificate, which Officers’
Certificate will state (i) that the Officers signing such Officers’ Certificate have supervised a review of the activities
of the Company and the Subsidiaries with a view to determining whether the Company has kept, observed, performed and fulfilled
its obligations under this Note during the preceding fiscal year; and (ii) to the best knowledge of each of the Officers signing
such Officers’ Certificate, (A) whether the Company has kept, observed, performed and fulfilled each and every covenant
contained in this Note and is not in default in the performance or observance of any of the terms, provisions and conditions of
this Note (without regard to any period of grace or requirement of notice provided under this Note) or, if one or more Defaults
or Events of Default have occurred, what events triggered such Defaults or Events of Default and what actions the Company is taking
or proposes to take with respect to such Defaults or Events of Default; and (B) whether any event has occurred and remains in existence
by reason of which any payment of the principal of, the Fundamental Change Repurchase Price for, or interest on, or any delivery
of any of the consideration due upon conversion of, this Note is prohibited, and, if any such event has occurred and remains in
existence, a description, in reasonable detail, of such event or events and what actions the Company is taking or proposes to take
with respect to such event or events.

 

(b)          Certificate
of Default or Event of Default. Within five (5) Business Days after a Default or Event of Default occurs, the Company will
deliver to the Holder an Officers’ Certificate describing such Default or Event of Default, its status and a description,
in reasonable detail, of what action the Company is taking or proposes to take with respect to such Default or Event of Default.

 

Section 4.06         Corporate
Existence. Subject to Article 5, the Company will do or cause to be done all things necessary to preserve and keep in
full force and effect:

 

(a)          its
corporate existence, and the corporate, partnership or other existence of each of the Subsidiaries, in accordance with the respective
organizational documents (as the same may be amended from time to time) of the Company or any such Subsidiary; and

 

(b)          the
rights (charter and statutory), licenses and franchises of the Company and the Subsidiaries;

 

provided, however, that the Company
will not be required to preserve or keep in full force and effect any such right, license or franchise, or the corporate, partnership
or other existence of any of the Subsidiaries, if the Board of Directors determines that the preservation thereof is no longer
desirable in the conduct of the business of the Company and the Subsidiaries, taken as a whole, and that the loss thereof is not
adverse in any material respect to the Holder.

 

Section 4.07         Par
Value Limitation. The Company will not take any action that, after giving effect to any adjustment pursuant to Section 8.05
or 8.07, would result in the Conversion Price becoming less than the par value of one share of Common Stock. In addition,
the Company will not engage in any transaction that would require an adjustment to the Conversion Rate pursuant to Section 8.06
that would cause the Conversion Price to be less than the par value of one share of Common Stock.

 

    	 	- 16 -	 

     

    

 

Section 4.08         Stay,
Extension and Usury Laws. The Company covenants that, to the extent that it may lawfully do so, it will not at any time insist
upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted,
now or at any time hereafter in force, that may affect the covenants or the performance of this Note.

 

Section 4.09         Further
Instruments and Acts. Upon request of the Holder, the Company will execute and deliver such further instruments and do such
further acts as may be reasonably necessary or proper to carry out more effectively the terms of this Note.

 

Article
5

CONSOLIDATION, MERGER AND SALE OF ASSETS

 

Section
5.01        Company May Consolidate, Merge or Sell Its Assets Only on Certain
Terms. The Company will not (1) consolidate with or merge with or into; or (2) sell, lease or otherwise transfer all
or substantially all of the consolidated assets of the Company and its Subsidiaries to, another Person (any such transaction,
a “Reorganization Event”), unless:

 

(a)          either:

 

(i)          the
Company is the surviving corporation; or

 

(ii)         the
resulting, surviving or transferee Person (if other than the Company) of such Reorganization Event (the “Reorganization
Successor Corporation”):

 

(I)         is
a corporation organized and validly existing under the laws of the United States of America, any State thereof or the District
of Columbia; and

 

(II)        expressly
assumes all of the obligations of the Company under this Note;

 

(b)          immediately
after giving effect to such Reorganization Event, no Default will have occurred and be continuing; and

 

(c)          prior
to the effective date of such Reorganization Event, the Company delivers to the Holder an Officers’ Certificate and an Opinion
of Counsel, each stating that:

 

(i)          such
Reorganization Event complies with Section 5.01(a);

 

(ii)         all
conditions precedent to such Reorganization Event provided in this Note have been satisfied; and

 

    	 	- 17 -	 

     

    

 

(iii)        this
Note constitutes the legal, valid and binding obligation of the Reorganization Successor Corporation (subject to customary limitations);

 

Section
5.02         Successor Substituted. If any Reorganization Event occurs that
complies with Sections 5.01(a)(ii) and 5.01(b), and the Company has complied with Section 5.01(c):

 

(a)          
from and after the date of such Reorganization Event, the Reorganization Successor Corporation for such Reorganization Event will
succeed to, and be substituted for, and may exercise every right and power of, and shall assume all obligations of, the Company
under this Note with the same effect as if such Reorganization Successor Corporation had been named as the Company herein.

 

(b)          except
in the case of a Reorganization Event that is a conveyance, transfer or lease of all or substantially all of the Company’s
assets, the Person named as the “Company” in the first paragraph of this Note or any successor (other than such Reorganization
Successor Corporation that will thereafter have become such in the manner prescribed in this Article 5) will be discharged
from its obligations under this Note and may be dissolved, wound up and liquidated at any time.

 

Article
6

DEFAULTS AND REMEDIES

 

Section
6.01         Events of Default.

 

(a)          General.
Each of the following events will be an “Event of Default”:

 

(i)          the
Company fails to pay the principal of this Note (including any Fundamental Change Repurchase Price) when due at maturity or upon
repurchase upon a Fundamental Change or declaration of acceleration or otherwise;

 

(ii)         the
Company fails to pay any interest on this Note when due and such failure continues for a period of thirty (30) days after the applicable
due date;

 

(iii)        the
Company fails to give any Fundamental Change Notice or notice of a Make-Whole Fundamental Change, in each case, when due;

 

(iv)        the
Company fails to comply with its obligation to convert this Note in accordance with Article 8 upon the Holder’s exercise
of its conversion rights with respect to this Note;

 

(v)         the
Company fails to comply with its obligations under Article 5;

 

(vi)        the
Company fails to perform or observe any of its covenants or warranties in this Note (other than a covenant or agreement specifically
addressed in clauses (i) through (v) above) and such failure continues for a period of sixty (60) days after days after written
notice to the Company by holders of at least 25% of the Series then outstanding;

 

    	 	- 18 -	 

     

    

 

(vii)       the
default by the Company or any Subsidiary with respect to any mortgage, agreement or other instrument under which there may be outstanding,
or by which there may be secured or evidenced, any indebtedness for money borrowed by the Company and/or any Subsidiary in excess
of one million dollars ($1,000,000) in the aggregate, whether such indebtedness exists as of the Issue Date or is later created,
if that default:

 

(A)         results
in such indebtedness becoming or being declared due and payable (prior to its express maturity); or

 

(B)         constitutes
a failure to pay the principal of, or interest on, such indebtedness when due and payable at its stated maturity, upon required
repurchase, upon declaration of acceleration or otherwise, and after the expiration of any applicable grace period,

 

and, such acceleration shall
not have been rescinded or annulled or such failure to pay shall not have been cured, as the case may be, within thirty (30) days
after written notice to the Company by the holders of at least 25% of the Series then outstanding;

 

(viii)      a
final judgment for the payment of in excess of one million dollars ($1,000,000) (excluding any amounts covered by insurance) is
rendered against the Company or any Subsidiary, and such judgment is not discharged or stayed within sixty (60) days after (i)
the date on which all rights to appeal such judgment have expired if no appeal has commenced; or (ii) the date on which all rights
to appeal have been extinguished;

 

(ix)         the
Company or any Significant Subsidiary, pursuant to or within the meaning of any Bankruptcy Law:

 

(A)        commences
a voluntary case;

 

(B)         consents
to the entry of an order for relief against it in an involuntary case;

 

(C)         consents
to the appointment of a Custodian of it or for any substantial part of its property;

 

(D)         makes
a general assignment for the benefit of its creditors;

 

(E)         takes
any comparable action under any foreign laws relating to insolvency; or

 

(F)         generally
is not paying its debts as they become due; or

 

(x)          a
court of competent jurisdiction enters an order or decree under any Bankruptcy Law that:

 

    	 	- 19 -	 

     

    

 

(A)        is
for relief against Company or any Significant Subsidiary in an involuntary case or proceeding;

 

(B)         appoints
a Custodian of the Company or any Significant Subsidiary, or for any substantial part of the property of the Company or any Significant
Subsidiary;

 

(C)         orders
the winding up or liquidation of the Company or any Significant Subsidiary; or

 

(D)         grants
any similar relief under any foreign laws,

 

and, in each such case, the order
or decree remains unstayed and in effect for sixty (60) days.

 

(b)          Cause
Irrelevant. Each of the events enumerated in Section 6.01(a) will constitute an Event of Default whatever the cause
and regardless of whether voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order
of any court or any order, rule or regulation of any administrative or governmental body.

 

Section
6.02         Acceleration.

 

(a)          Automatic
Acceleration in Certain Circumstances. If an Event of Default specified in Sections 6.01(a)(ix) or 6.01(a)(x)
occurs with respect to the Company, the principal amount of, and all accrued and unpaid interest, if any, on this Note will immediately
become due and payable without any further action or notice by any party.

 

(b)          Optional
Acceleration. If any Event of Default other than an Event of Default specified in Section 6.01(a)(ix) or 6.01(a)(x)
occurs and is continuing, the holders of at least 25% of the aggregate principal amount of the Series then outstanding, by delivering
a written notice to the Company, may declare the principal amount of, and all accrued and unpaid interest, if any, on all then
outstanding notes in the Series immediately due and payable, and upon such declaration, the principal amount of, and all accrued
and unpaid interest, if any, on all then outstanding notes in the Series will immediately become due and payable.

 

(c)          Rescission
of Acceleration. Notwithstanding anything to the contrary in this Note, holders of a majority of the aggregate principal amount
of the Series then outstanding may, on behalf of the holders of all then outstanding notes in the Series, rescind any acceleration
of such notes and its consequences hereunder by delivering written notice to the Company if (i) such rescission would not conflict
with any judgment or decree of a court of competent jurisdiction; and (ii) all existing Events of Default (other than the nonpayment
of the principal of, interest, if any, on, or the Fundamental Change Repurchase Price for, the notes in the Series that have become
due solely as a result of acceleration) have been cured or waived. No such rescission will affect any subsequent Default or impair
any right consequent thereto.

 

Section 6.03         Other
Remedies. If an Event of Default occurs and is continuing, the Holder may pursue any available remedy to collect the payment
of principal, accrued and unpaid interest, if any, or payment of the Fundamental Change Repurchase Price for, this Note or to enforce
the performance of any provision of this Note regarding any other matter.

 

    	 	- 20 -	 

     

    

 

A delay or omission by the Holder in exercising
any right or remedy accruing upon an Event of Default will not impair the right or remedy or constitute a waiver of or acquiescence
in the Event of Default. No remedy is exclusive of any other remedy. All available remedies are cumulative.

 

Section
6.04         Sole Remedy for Failure to Report.

 

(a)          General.
Notwithstanding anything to the contrary in this Note, the Company may elect that the sole remedy for any Event of Default specified
in Section 6.01(a)(vi) relating to the Company’s failure to comply with Section 4.03 (a “Reporting
Event of Default”) will, for the period beginning on the date on which such Reporting Event of Default first occurred
and ending on the earlier of (A) the date on which such Reporting Event of Default (i) is cured; or (ii) is validly waived in accordance
with Section 6.05; and (B) the sixtieth (60th) calendar day immediately following the date on which such Reporting Event
of Default first occurred, consist exclusively of the right to receive additional interest (the “Special Interest”)
on this Note at a rate equal to 0.50% per annum on the principal amount of this Note. Any Special Interest will be payable in the
same manner and on the same dates as the stated interest payable on this Note and will accrue in addition to any Additional Interest
that the Company is obligated to pay.

 

(b)          Limitation
on Remedy. If (i) a Reporting Event of Default occurs and the Company elects that the sole remedy with respect to such Reporting
Event of Default will be the Special Interest; and (ii) on the sixty first (61st) day immediately following, and including, the
date on which such Reporting Event of Default first occurred, such Reporting Event of Default has not been cured or validly waived
in accordance with Section 6.05, then this Note will become subject to acceleration under Section 6.02(a) on account
of such Reporting Event of Default. For the avoidance of doubt, Special Interest will cease to accrue from such sixty first (61st)
day, without limiting the generality of this Section 6.04 as it may apply to any subsequent Reporting Event of Default.

 

(c)          Company
Election Notice. To elect to pay the Special Interest as the sole remedy for a Reporting Event of Default, the Company must
deliver written notice of such election to the Holder prior to the date on which such Reporting Event of Default first occurs.
Any such notice must include a brief description of the report that the Company failed, or will fail, to file, a statement that
the Company is electing to pay the Special Interest and the date on which such Reporting Event of Default will occur. If a Reporting
Event of Default occurs and the Company fails to timely deliver such notice for such Reporting Event of Default or fails to pay
the Special Interest, this Note will be subject to acceleration under Section 6.02(a) on account of such Reporting Event
of Default.

 

(d)          Other
Events of Default. Notwithstanding anything to the contrary herein, if the Company elects to pay Special Interest with respect
to any Reporting Event of Default, the Company’s election will not affect the rights of the Holder with respect to any other
Event of Default, including with respect to any other Reporting Event of Default; provided, that, for the avoidance of doubt,
in no event will the Company be obligated to pay Special Interest at a rate greater than 0.50% per annum on the principal amount
of this Note.

 

    	 	- 21 -	 

     

    

 

 

Section 6.05         Waiver
of Past Defaults. If an Event of Default described in Sections 6.01(a)(i), 6.01(a)(ii), 6.01(a)(iv) or
6.01(a)(vi) (which, in the case of Section 6.01(a)(vi) only, relates to a covenant that cannot be amended without
the consent of each affected holder of a note in the Series) or a Default that would lead to such an Event of Default occurs and
is continuing, such Event of Default or Default may be waived only with the consent of each affected holder of a note in the Series.
Every other Event of Default or Default may be waived by the holders of a majority of the aggregate principal amount of the outstanding
Series (including consents obtained in connection with a repurchase of, or tender offer or exchange offer for, notes in the Series).
Whenever any Event of Default is so waived, it will cease to exist, and whenever any Default is so waived, it will be deemed cured
and any Event of Default arising therefrom will be deemed not to occur. However, no such waiver will extend to any subsequent or
other Default or Event of Default or impair any consequent right

 

Article
7

SATISFACTION AND DISCHARGE

 

Section 7.01         Discharge
of Liability on Note. When (a) this Note becomes due and payable, and the Company delivers to the Holder, as applicable, cash
(or, solely to satisfy amounts due and owing as a result of conversions of this Note, Conversion Consideration), sufficient to
pay all amounts due and owing on this Note and (b) the Company pays all other sums payable by it under this Note, this Note will
cease to be of further effect and the Holder will acknowledge the satisfaction and discharge of this Note.

 

Article
8

CONVERSIONS

 

Section
8.01           Right To Convert.

 

(a)          In
General. Subject to, and upon compliance with, the provisions of this Article 8, at any time prior to the Close of Business
on the second (2nd) Business Day immediately preceding the Maturity Date, the Holder may, at its option, convert this Note (or
any portion thereof) into Conversion Consideration, as provided in this Article 8. This Note may not be converted after
the Close of Business on the second (2nd) Business Day immediately preceding the Maturity Date.

 

(b)          Closed
Periods. Notwithstanding anything to the contrary in this Note, if the Holder tenders a Repurchase Notice with respect to this
Note in accordance with Article 3, this Note may not be converted except to the extent (i) this Note is not subject to such
Repurchase Notice, (ii) such Repurchase Notice is withdrawn in accordance with Article 3 or (iii) the Company fails to pay
the Fundamental Change Repurchase Price for this Note in accordance with Section 3.05(b).

 

    	 	- 22 -	 

     

    

 

Section
8.02         Conversion Procedures.

 

(a)          General.
To exercise its conversion right with respect to this Note, the Holder must (i) complete and manually sign a conversion notice
in the form set forth in Exhibit A hereto, or a facsimile of such conversion notice (such notice, or such facsimile, the
“Conversion Notice”); (ii) deliver such signed and completed Conversion Notice, which shall be irrevocable,
and this Note to the Company; (iii) furnish any endorsements and transfer documents that the Company may require; and (iv) pay
any amounts due pursuant to Section 8.02(d) or 8.02(e). The first Business Day on which the Holder satisfies the
foregoing requirements with respect to this Note and on which conversion of this Note is not otherwise prohibited hereunder will
be the “Conversion Date” for this Note. If the Holder has delivered a Fundamental Change Repurchase Notice with
respect to this Note, the Holder may not surrender this Note for conversion until the Holder has withdrawn such Fundamental Change
Repurchase Notice in accordance with Section 3.04. The conversion of this Note will be deemed to occur at the Close of Business
on the Conversion Date for this Note, and this converted Note or portion thereof will cease to be outstanding upon conversion.

 

(b)          Holder
of Record. If the Holder surrenders the entire principal amount of this Note for conversion, the Holder will no longer be the
Holder of this Note as of the Close of Business on the Conversion Date for this Note. The person in whose name any shares of Common
Stock are issuable upon conversion of this Note will become the holder of record of such shares as of the Close of Business on
the Conversion Date for such conversion.

 

(c)          Conversions
in Part. If the Holder surrenders only a portion of the principal amount of this Note for conversion, promptly after the Conversion
Date for such portion, the Company will deliver to the Holder a new Note, having a principal amount equal to the aggregate principal
amount of the unconverted portion of the Note surrendered for conversion.

 

(d)          Reimbursement
of Interest upon Conversion. If the Holder converts this Note after the Close of Business on a Regular Record Date, but prior
to the Open of Business on the Interest Payment Date corresponding to such Regular Record Date, then (x) the Holder at the Close
of Business on such Regular Record Date shall be entitled, notwithstanding such conversion, to receive, on the date the Company
delivers (or is required to deliver) the Conversion Consideration due in respect of such conversion, the unpaid interest that would
have accrued on such Note to, but excluding, such Interest Payment Date (assuming, solely for these purposes, that such Note remained
outstanding through such Interest Payment Date); and (y) the Holder must, upon surrender of this Note for conversion, accompany
this Note with an amount of cash equal to the amount of such interest referred to in clause (x) above; provided, however,
that the Holder need not make such payment (A) for conversions following the Regular Record Date immediately preceding the Maturity
Date; (B) if the Company has specified a Fundamental Change Repurchase Date that is after such Regular Record Date and on or prior
to the Business Day immediately following such Interest Payment Date; or (C) to the extent of any overdue interest, if any overdue
interest exists at the time of conversion with respect to this Note. For the avoidance of doubt, the Holder at the Close of Business
on the Regular Record Date immediately preceding the Maturity Date will be entitled to receive interest that accrues (or would
have accrued) on this Note to, but excluding, the Maturity Date notwithstanding any conversion of this Note.

 

    	 	- 23 -	 

     

    

 

(e)         Taxes
and Duties. If the Holder converts this Note, the Company will pay any documentary, stamp or similar issue or transfer tax
due on the issue of any shares of the Common Stock upon the conversion; provided, however, that if any tax is due
because the Holder requested that shares of Common Stock be issued in a name other than its own, the Holder will pay such tax and
the Company, until having received a sum sufficient to pay such tax, may refuse to deliver any certificates representing the shares
of Common Stock being issued in a name other than that of the Holder.

 

(f)         Restrictions
on Conversion. Notwithstanding anything to the contrary in this Note, this Note will not be convertible by the Holder, and
the Company will not effect any conversion of this Note, in each case to the extent (and only to the extent) that such convertibility
or conversion would result in the Holder or any of its Affiliates beneficially owning in excess of 9.99% of the then-outstanding
shares of Common Stock. For these purposes, beneficial ownership and all determinations and calculations (including with respect
to calculations of percentage ownership) will be determined in accordance with Section 13(d) of the Exchange Act and the rules
and regulations promulgated thereunder. For the avoidance of doubt, if the convertibility of this Note is restricted pursuant to
this Section 8.02(f), this Note will continue to be outstanding, and its convertibility will be reinstated if and when the
convertibility and conversion will not violate the limitations set forth in this Section 8.02(f).

 

Section
8.03         Settlement Upon Conversion.

 

(a)          Conversion
Obligation.

 

(i)          Conversion
Consideration. Subject to the terms hereof, upon conversion of this Note, the consideration (the “Conversion Consideration”)
due in respect of each $1,000 principal amount of this Note to be converted will consist of (I) a whole number of shares of Common
Stock equal to the Conversion Rate in effect on the Conversion Date for such conversion (which, if not a whole number, will be
rounded down to the nearest whole number); (II) in the case of a principal amount or portion of a principal amount that is not
a multiple of $1,000, an equivalent pro rata number of shares and (III) if such Conversion Rate is not a whole number, cash in
lieu of the related fractional share in an amount equal to the product of (x) the Last Reported Sale Price per share of Common
Stock on such Conversion Date (or, if such Conversion Date is not a Trading Day, the immediately preceding Trading Day) and (y)
the fractional portion of such Conversion Rate.

 

(ii)         Delivery
of Conversion Consideration. Except as set forth in Section 8.05, the Company will pay or deliver, as the case
may be, the Conversion Consideration due upon the conversion of this Note to the Holder on the third (3rd) Business Day immediately
following the Conversion Date for such conversion.

 

(b)          Settlement
of Accrued Interest and Deemed Payment of Principal. If the Holder converts this Note, the Company will not adjust the Conversion
Rate to account for any accrued and unpaid interest on this Note, and, except as provided in Section 8.02(d), the Company’s
delivery of the Conversion Consideration due upon such conversion will be deemed to satisfy and discharge in full the Company’s
obligation to pay the principal of this Note and accrued and unpaid interest, if any, on, this Note to, but excluding the Conversion
Date. As a result, except as provided in Section 8.02(d), any accrued and unpaid interest with respect to this Note, in
the event that it is converted, will be deemed to be paid in full rather than cancelled, extinguished or forfeited.

 

    	 	- 24 -	 

     

    

 

Section
8.04         Common Stock Issued Upon Conversion.

 

(a)          The
Company will reserve out of its authorized but unissued shares of Common Stock, and keep available to satisfy conversion of this
Note, a number of shares of Common Stock sufficient to permit the conversion this Note, after giving effect to the largest number
of Additional Shares that may from time to time be added to the Conversion Rate as provided in Section 8.07.

 

(b)          Any
shares of Common Stock delivered upon the conversion of this Note will be newly issued shares or treasury shares, duly and validly
issued, fully paid, nonassessable, free from preemptive rights and free of any lien or adverse claim (except to the extent of any
lien or adverse claim created by the action or inaction of the Holder or other Person to whom such shares of Common Stock will
be delivered). In addition, the Company will endeavor to comply promptly with all federal and state securities laws regulating
the offer and delivery of any shares of Common Stock issuable upon conversion of this Note. The Company will also use its best
efforts to cause any shares of Common Stock issuable upon conversion of this Note to be listed on whatever stock exchange(s) the
Common Stock is listed on the date the Holder becomes a record holder of such Common Stock.

 

Section 8.05         Adjustment
of Conversion Rate. The Company will adjust the Conversion Rate from time to time as described in this Section 8.05,
except that the Company will not make an adjustment to the Conversion Rate if the Holder participates (other than in a share split
or share combination), at the same time and upon the same terms as holders of the Common Stock, and solely as a result of holding
this Note, in the relevant transaction described in this Section 8.05 without having to convert its Note and as if it held
a number of shares of the Common Stock equal to the product of (i) the Conversion Rate in effect on the applicable record date,
Effective Date or expiration date; and (ii) the aggregate principal amount of this Note (expressed in thousands) on such date.

 

(a)          Stock
Dividends and Share Splits. If the Company exclusively issues to all or substantially all holders of the Common Stock shares
of Common Stock as a dividend or distribution on shares of the outstanding Common Stock, or if the Company effects a share split
of the Common Stock or a share combination of the Common Stock (excluding an issuance solely pursuant to a Common Stock Change
Event, as to which the provisions set forth in Section 8.08(a) will apply), the Conversion Rate will be adjusted based on
the following formula:

 

 

 

where:

 

		CR0	=	the Conversion Rate in effect immediately prior to the Open of Business on the Ex-Dividend Date of such dividend or distribution,
or immediately prior to the Open of Business on the Effective Date of such share split or share combination, as applicable;

 

    	 	- 25 -	 

     

    

 

		CR1	=	the Conversion Rate in effect immediately after the Open of Business on such Ex-Dividend Date or Effective Date, as applicable;

 

		OS0	=	the number of shares of Common Stock outstanding immediately prior to the Open of Business on such Ex-Dividend Date or Effective
Date, as applicable; and

 

		OS1	=	the number of shares of Common Stock outstanding immediately after giving effect to such dividend, distribution, share split or
share combination, as applicable.

 

Such adjustment shall become effective
immediately after the Open of Business on such Ex-Dividend Date or Effective Date, as applicable. If any dividend, distribution,
share split or share combination of the type described in this Section 8.05(a) is declared, but not so paid or made, the
Conversion Rate will be immediately readjusted, effective as of the date the Board of Directors determines not to pay such dividend
or distribution or to effect such share split or share combination, to the Conversion Rate that would then be in effect if such
dividend, distribution, share split or share combination had not been declared or announced.

 

(b)          Rights,
Options and Warrants. If the Company issues, to all or substantially all holders of its outstanding Common Stock, rights, options
or warrants entitling such holders, for a period of not more than sixty (60) calendar days after the record date of such issuance,
to subscribe for, or purchase, shares of Common Stock, at a price per share less than the average of the Last Reported Sale Prices
per share of the Common Stock for the ten (10) consecutive Trading Day period ending on, and including, the Trading Day immediately
preceding the date of announcement of such issuance, then, subject to the provisions described below with respect to rights issued
pursuant to a stockholder rights plan, the Conversion Rate will be increased based on the following formula:

 

 

 

where:

 

		CR0	=	the Conversion Rate in effect immediately prior to the Open of Business on the Ex-Dividend Date for such issuance;

 

		CR1	=	the Conversion Rate in effect immediately after the Open of Business on such Ex-Dividend Date;

 

		OS	=	the number of shares of Common Stock outstanding immediately prior to the Open of Business on such Ex-Dividend Date;

 

		X	=	the total number of shares of Common Stock issuable pursuant to such rights, options or warrants; and

 

	 	Y	=	the number of shares of Common Stock equal to the quotient of (i) the aggregate price payable to exercise such rights, options
or warrants, over (ii) the average of the Last Reported Sale Prices per share of the Common Stock over the ten (10) consecutive
Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of the issuance of
such rights, options or warrants.

 

    	 	- 26 -	 

     

    

 

Such adjustment shall become effective
immediately after the Open of Business on such Ex-Dividend Date. To the extent that shares of Common Stock are not delivered after
the expiration of such rights, options or warrants, including because the issued rights, options or warrants were not exercised,
the Conversion Rate will be readjusted to the Conversion Rate that would then be in effect had the increase with respect to the
issuance of such rights, options or warrants been made on the basis of delivery of only the number of shares of Common Stock actually
delivered. If such rights, options or warrants are not so issued, the Conversion Rate will be readjusted to the Conversion Rate
that would then be in effect if the Ex-Dividend Date for such issuance had not occurred.

 

For purposes of this Section 8.05(b),
in determining whether any rights, options or warrants entitle holders of the Common Stock to subscribe for, or purchase, shares
of Common Stock at a price per share less than the average of the Last Reported Sale Prices per share of Common Stock for the ten
(10) consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement for
an issuance, and in determining the aggregate price payable to exercise such rights, options or warrants, there will be taken into
account any consideration received by the Company for such rights, options or warrants and any amount payable on exercise thereof,
the value of such consideration, if other than cash, to be determined by the Board of Directors.

 

(c)          Spin-Offs
and Other Distributed Property.

 

(i)          If
the Company distributes shares of its Capital Stock, evidences of its indebtedness or other assets or property of the Company,
or rights, options or warrants to acquire Capital Stock of the Company or other securities, to all or substantially all holders
of the Common Stock, excluding:

 

(A)         dividends,
distributions, rights, options or warrants for which an adjustment was effected pursuant to Section 8.05(a) or 8.05(b),
as applicable;

 

(B)         dividends
or distributions paid exclusively in cash for which an adjustment was effected pursuant to Section 8.05(d);

 

(C)         Spin-Offs
for which the provisions described in Section 8.05(c)(ii) will apply; and

 

(D)         an
issuance solely pursuant to a Common Stock Change Event, as to which the provisions set forth in Section 8.08(a) will apply,

 

    	 	- 27 -	 

     

    

 

then the Conversion Rate will
be increased based on the following formula:

 

 

 

where:

 

		CR0	=	the Conversion Rate in effect immediately prior to the Open of Business on the Ex-Dividend Date for such distribution;

 

		CR1	=	the Conversion Rate in effect immediately after the Open of Business on such Ex-Dividend Date;

 

		SP0	=	the average of the Last Reported Sale Prices per share of the Common Stock over the ten (10) consecutive Trading Day period ending
on, and including, the Trading Day immediately preceding the Ex-Dividend Date for such distribution; and

 

		FMV	=	the fair market value (as determined by the Board of Directors) of the shares of Capital Stock, evidences of indebtedness, assets,
property, rights, options or warrants distributed with respect to each outstanding share of Common Stock on the Ex-Dividend Date
for such distribution.

 

Such adjustment shall become
effective immediately after the Open of Business on such Ex-Dividend Date. Notwithstanding the foregoing, if “FMV”
(as defined above) is equal to or greater than the “SP0” (as defined above), in lieu of the foregoing increase,
the Holder will receive, for each $1,000 principal amount of this Note outstanding on the record date for the distribution, at
the same time and upon the same terms as holders of the Common Stock, the amount and kind of shares of Capital Stock, evidences
of indebtedness, assets or property, rights, options or warrants or other securities that the Holder would have received if the
Holder had owned a number of shares of Common Stock equal to the Conversion Rate in effect on the record date for such distribution
(or in the case of a principal amount or portion of a principal amount that is not a multiple of $1,000, an equivalent pro rata
amount).

 

If any distribution of the type
described in this Section 8.05(c)(i) is not so paid or made, or if any rights, options or warrants are not exercised before
their expiration date, the Conversion Rate will be readjusted to be the Conversion Rate that would then be in effect if such distribution
had not been declared.

 

(ii)         With
respect to an adjustment pursuant to this Section 8.05(c) where there has been a payment of a dividend or other distribution
on the Common Stock of shares of Capital Stock of any class or series, or similar equity interest, of or relating to an Affiliate,
a Subsidiary or other business unit of the Company, and such Capital Stock or similar equity interest is listed or quoted (or will
be listed or quoted upon the consummation of the transaction) on a national securities exchange or a reasonably comparable non-U.S.
equivalent (a “Spin-Off”), but excluding an issuance solely pursuant to a Common Stock Change Event as to which
the provisions described in Section 8.08(a) apply, the Conversion Rate will be increased based on the following formula:

 

    	 	- 28 -	 

     

    

 

 

 

where:

 

		CR0	=	the Conversion Rate in effect immediately prior to the Open of Business on the Ex-Dividend Date for such Spin-Off;

 

		CR1	=	the Conversion Rate in effect immediately after the Open of Business on such Ex-Dividend Date;

 

		FMV0	=	the average of the Last Reported Sale Prices of the Capital Stock or similar equity interest distributed to holders of the Common
Stock applicable to one share of Common Stock (determined for purposes of the definition of Last Reported Sale Price as if such
Capital Stock or similar equity interest were the Common Stock) over the first ten (10) consecutive Trading Day period after,
and including, the Ex-Dividend Date of the Spin-Off (the “Valuation Period”); and

 

		MP0	=	the average of the Last Reported Sale Prices per share of the Common Stock over the Valuation Period.

 

Such adjustment shall become
effective immediately after the Open of Business on such Ex-Dividend Date. The adjustment to the Conversion Rate under this Section
8.05(c)(ii) will be calculated as of the Close of Business on the last Trading Day of the Valuation Period but will be given
effect as of immediately after the Open of Business on the Ex-Dividend Date of the Spin-Off. Notwithstanding anything to the contrary
herein or in this Note, if necessary, the Company shall delay the settlement of any conversion of this Note where the Conversion
Date occurs during the Valuation Period until the third (3rd) Business Day after the last day of the Valuation Period. If any distribution
of the type described in this Section 8.05(c)(ii) is declared but not so made, the Conversion Rate shall be immediately
readjusted, effective as of the date the Board of Directors determines not to make such distribution, to the Conversion Rate that
would then be in effect if such distribution had not been declared.

 

(d)          Cash
Dividends or Distributions. If any cash dividend or distribution (other than a distribution as to which an adjustment to the
Conversion Rate was effected pursuant to Section 8.05(e)) is made to all or substantially all holders of the Common Stock,
the Conversion Rate will be increased based on the following formula:

 

 

 

    	 	- 29 -	 

     

    

 

where:

 

		CR0	=	the Conversion Rate in effect immediately prior to the Open of Business on the Ex-Dividend Date for such dividend or distribution;

 

		CR1	=	the Conversion Rate in effect immediately after the Open of Business on the Ex-Dividend Date for such dividend or distribution;

 

		SP0	=	the Last Reported Sale Price per share of the Common Stock on the Trading Day immediately preceding the Ex-Dividend Date for such
dividend or distribution; and

 

		C	=	the amount in cash per share the Company distributes to holders of Common Stock.

 

Such adjustment shall become effective
immediately after the Open of Business on such Ex-Dividend Date. Notwithstanding the foregoing, if “C” (as defined
above) is equal to or greater than “SP0” (as defined above), in lieu of the foregoing increase, the Holder
will receive, for each $1,000 principal amount of this Note outstanding on the record date for such cash dividend or distribution,
at the same time and upon the same terms as holders of the Common Stock, the amount of cash that the Holder would have received
if the Holder had owned a number of shares of Common Stock equal to the Conversion Rate in effect on such record date (or in the
case of a principal amount or portion of a principal amount that is not a multiple of $1,000, an equivalent pro rata number of
shares). If any dividend or distribution of the type described in this Section 10.05(d) is declared but not so paid
or made, the Conversion Rate will be readjusted to the Conversion Rate that would then be in effect if such dividend or distribution
had not been declared.

 

(e)          Tender
Offers or Exchange Offers. If the Company or any Subsidiary makes a payment in respect of a tender offer or exchange offer
for the Common Stock, to the extent that the cash and value of any other consideration included in the payment per share of Common
Stock exceeds the Last Reported Sale Price per share of the Common Stock on the Trading Day next succeeding the last date (the
“Expiration Date”) on which tenders or exchanges may be made pursuant to such tender offer or exchange offer
(as it may be amended), the Conversion Rate will be increased based on the following formula:

 

 

where:

 

		CR0	=	the Conversion Rate in effect immediately prior to the Expiration Time (as defined below);

 

		CR1	=	the Conversion Rate in effect immediately after the Expiration Time;

 

    	 	- 30 -	 

     

    

 

		AC	=	the aggregate value of all cash and any other consideration (as determined by the Board of Directors) paid or payable for shares
purchased in such tender or exchange offer;

 

		OS0	=	the number of shares of Common Stock outstanding immediately prior to the time (the “Expiration Time”)
on the date such tender or exchange offer expires (prior to giving effect to the purchase of all shares accepted for purchase
or exchange in such tender or exchange offer);

 

		OS1	=	the number of shares of Common Stock outstanding immediately after the Expiration Time (after giving effect to the purchase of
all shares accepted for purchase or exchange in such tender or exchange offer); and

 

		SP1	=	the average of the Last Reported Sale Prices per share of the Common Stock over the ten (10) consecutive Trading Day period (the
“Averaging Period”) commencing on the Trading Day next succeeding the Expiration Date.

 

The adjustment to the Conversion Rate pursuant
to this Section 8.05(e) will be calculated as of the Close of Business on the last Trading Day of the Averaging Period but
will be given effect as of immediately after the Expiration Time. Notwithstanding anything to the contrary herein, if necessary,
the Company shall delay the settlement of any conversion of this Note where the Conversion Date occurs during the Averaging Period
until the third (3rd) Business Day after the last day of the Averaging Period.

 

(f)          Successive
Adjustments. After an adjustment to the Conversion Rate under this Article 8, any subsequent event requiring an adjustment
under this Article 8 will cause an adjustment to the Conversion Rate as so adjusted, without duplication.

 

(g)          Limitations
Imposed by Stock Market Listing Standards. The Company will not enter into any transaction, or take any other voluntary action,
that would result in an adjustment to the Conversion Rate that would violate the listing standards of any securities exchange on
which any securities of the Company may be then listed, without complying, if applicable, with the requirements of such listing
standards.

 

(h)          Special
Settlement Provisions. Notwithstanding anything to the contrary herein, if:

 

(i)          this
Note is to be converted and, as of the Conversion Date for such conversion, any transaction or other event that requires an adjustment
to the Conversion Rate pursuant to Sections 8.05(a) through (e) has occurred but has not yet resulted in an adjustment
to the Conversion Rate;

 

(ii)         the
consideration due upon such conversion consists of any shares of Common Stock; and

 

(iii)        such
shares of Common Stock are not entitled to participate in such transaction or event because they were not held on the related record
date or otherwise, then, solely for purpose of such conversion, the Company shall, without duplication, give effect to such adjustment
on such Conversion Date.

 

    	 	- 31 -	 

     

    

 

In addition, notwithstanding anything to
the contrary herein, if:

 

(i)          a
Conversion Rate adjustment for any transaction or other event becomes effective on any Ex-Dividend Date pursuant to Sections
8.05(a) through (e);

 

(ii)         this
Note is to be converted;

 

(iii)        the
Conversion Date for such conversion occurs on or after such Ex-Dividend Date and on or before the related record date;

 

(iv)        the
consideration due upon such conversion includes any whole shares of Common Stock; and

 

(v)         the
Holder would be treated, on such record date, as the record holder of such shares of Common Stock based on a Conversion Rate that
is adjusted for such event,

 

then such Conversion Rate adjustment shall
not be given effect for such conversion. Instead, the Holder will be treated as if the Holder were, as of such record date, the
record holder of such shares of Common Stock on an unadjusted basis and will participate in such transaction or event.

 

(i)          Shareholder
Rights Plans. If the Company has a rights plan in effect when the Holder converts this Note, the Company will deliver to the
Holder, to the extent the Holder receives any shares of Common Stock upon such conversion of this Note, any rights that, under
the rights plan, would be applicable to a share of Common Stock, unless prior to the Conversion Date for this Note, the rights
have separated from the Common Stock, in which case, and only in such case, the Conversion Rate will be adjusted pursuant to Section
8.05(c)(i) as if, at the time of such separation, the Company had distributed to all holders of the Common Stock shares of
its Capital Stock, evidences of its indebtedness, other assets or property of the Company or rights, options or warrants to acquire
its Capital Stock or other securities, subject to readjustment in the event of the expiration, termination or redemption of such
rights.

 

(j)          Other
Adjustments. Whenever any provision of this Note requires the calculation of the Last Reported Sale Price or a function thereof
over a period of multiple days (including the Stock Price for purposes of a Make-Whole Fundamental Change), the Company will make
appropriate adjustments to account for any adjustment to the Conversion Rate that becomes effective, or any event requiring an
adjustment to the Conversion Rate where the Ex-Dividend Date, Effective Date or expiration date of the event occurs, at any time
during such period.

 

(k)          Restrictions
on Adjustments. Except as a result of a reverse share split or a share combination subject to Section 8.05(a), and except
for readjustments pursuant to the last paragraph of Section 8.05(a), readjustments pursuant to the penultimate paragraph
of Section 8.05(b), readjustments pursuant to the last paragraph of Section 8.05(c)(i), readjustments pursuant to
the penultimate paragraph of Section 8.05(c)(ii) and readjustments pursuant to Section 8.05(d), in no event will
the Conversion Rate be adjusted downward pursuant to Section 8.05(a), (b), (c), (d) or (e).
In addition, notwithstanding anything to the contrary elsewhere in this Note, the Conversion Rate will not be adjusted:

 

    	 	- 32 -	 

     

    

 

(i)          upon
the issuance of any shares of Common Stock pursuant to any present or future plan providing for the reinvestment of dividends or
interest payable on the Company’s securities and the investment of additional optional amounts in shares of Common Stock
under any plan;

 

(ii)         upon
the issuance of any shares of Common Stock or options or rights to purchase those shares pursuant to any present or future employee,
director or consultant benefit plan or program of, or assumed by, the Company or any of its Subsidiaries;

 

(iii)        upon
the issuance of any shares of Common Stock pursuant to any option, warrant, right or exercisable, exchangeable or convertible security
not described in the preceding clause and outstanding as of the date of the Issue Date;

 

(iv)        upon
the repurchase of any shares of Common Stock pursuant to an open-market share repurchase program or other buy-back transaction
that is not a tender offer or exchange offer subject to Section 10.05(e);

 

(v)         for
a change in the par value of the Common Stock; or

 

(vi)        for
accrued and unpaid interest.

 

(l)          Miscellaneous.

 

(i)          Certain
Definitions.

 

(II)        For
purposes of this Section 8.05, the number of shares outstanding at any time will include shares issuable in respect of scrip
certificates issued in lieu of fractions of shares of Common Stock; but, so long as the Company does not pay any dividend or make
any distribution on shares of Common Stock held in the treasury of the Company, will not include shares of Common Stock held in
the treasury of the Company.

 

(III)       For
purposes of this Section 8.05, the term “Effective Date” will mean the first date on which the Common
Stock trades on the applicable exchange or in the applicable market, regular way, reflecting the relevant share split or share
combination, as applicable.

 

(IV)        For
purposes of this Article 8, the term “Ex-Dividend Date” will mean the first date on which the shares
of the Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive the
issuance, dividend or distribution in question.

 

    	 	- 33 -	 

     

    

 

(ii)         Notices.
Whenever the Company adjusts (or is required to adjust) the Conversion Rate pursuant to this Section 8.05, the Company will
promptly deliver to the Holder a written notice, which notice will include (i) a brief description of the event requiring adjustment
to the Conversion Rate pursuant to this Section 8.05; (ii) the effective time of such adjustment; (iii) the Conversion Rate
in effect immediately after such adjustment is made; and (iv) a schedule explaining, in reasonable detail, how the Company calculated
such adjustment.

 

(iii)        All
calculations and other determinations in respect of the Conversion Rate will be made by the Company to the nearest 1/10,000th of
a share, with 5/100,000ths rounded upward.

 

Section
8.06         Voluntary Adjustments.

 

(a)          Best
Interest Increases. The Company may, from time to time, to the extent permitted by law and the applicable rules of any exchange
on which the Common Stock is listed, increase the Conversion Rate by any amount if (i) the Board of Directors determines that such
increase is in the best interest of the Company; (ii) such increase is in effect for a period of at least twenty (20) Business
Days; and (iii) during such period, such increase is irrevocable.

 

(b)          Tax-Related
Increases. To the extent permitted by law and the applicable rules of any exchange on which the Common Stock is listed, the
Company may (but is not required to) increase the Conversion Rate if the Board of Directors determines that such increase is advisable
to avoid, or diminish, any income tax imposed on holders of the Common Stock or rights to purchase the Common Stock as a result
of any dividend or distribution of shares (or rights to acquire shares) or similar event treated as such for U.S. federal income
tax purposes.

 

(c)          Notices.
Whenever the Board of Directors determines that the Company will increase the Conversion Rate pursuant to this Section 8.06,
the Company will deliver to the Holder notice of such increase at least fifteen (15) Business Days before such increase will take
effect, which notice will state the increase to be made and the period during which such increase will be in effect.

 

Section
8.07         Adjustments Upon Certain Fundamental Changes.

 

(a)          General.
If a Fundamental Change (determined after giving effect to the penultimate paragraph of the definition thereof, but without regard
to the exclusion in clause (b)(ii) of the definition thereof) occurs (a “Make-Whole Fundamental Change”), and
the Holder converts this Note “in connection with” such Make-Whole Fundamental Change, the Company will, in the circumstances
described in this Section 8.07, increase the Conversion Rate for this Note by the number of additional shares of Common
Stock (the “Additional Shares”) set forth in this Section 8.07. For purposes of this Section 8.07,
a conversion of this Note will be deemed to be “in connection with” a Make-Whole Fundamental Change if the applicable
Conversion Date occurs during the period from, and including, the effective date of the Make-Whole Fundamental Change up to, and
including, the Business Day immediately prior to the related Fundamental Change Repurchase Date (or, in the case of a Make-Whole
Fundamental Change that would have been a Fundamental Change but for the exclusion in clause (b)(ii) of the definition thereof,
the thirty fifth (35th) Trading Day immediately following the effective date of such Make-Whole Fundamental Change). As promptly
as practicable, but in no event later than the Business Day after the effective date of a Make-Whole Fundamental Change, the Company
will notify the Holder of such effective date.

 

    	 	- 34 -	 

     

    

 

(b)          Determination
of Additional Shares. The number of Additional Shares, if any, by which the Conversion Rate will be increased if the Holder
converts this Note in connection with a Make-Whole Fundamental Change will be determined by reference to the table below, and will
be based on the Make-Whole Fundamental Change Effective Date and the Stock Price for such Make-Whole Fundamental Change. For any
Make-Whole Fundamental Change, the “Make-Whole Fundamental Change Effective Date” will mean the date on which
such Make-Whole Fundamental Change occurs or becomes effective.

 

(c)          Adjustment
of Stock Prices and Additional Shares. The Stock Prices set forth in the first row (i.e., the column headers) of the
table below will be adjusted on each date on which the Conversion Rate must be adjusted pursuant to Section 8.05. The adjusted
Stock Prices will equal the Stock Prices in effect immediately prior to such adjustment, multiplied by a fraction, (i) the numerator
of which is the Conversion Rate in effect immediately prior to the adjustment giving rise to the share price adjustment; and (ii)
the denominator of which is the Conversion Rate in effect immediately after the adjustment. The numbers of Additional Shares set
forth in the table below will be adjusted in the same manner, at the same time and for the same events for which the Conversion
Rate is adjusted pursuant to Section 8.05.

 

(d)          Additional
Shares Table. The following table sets forth hypothetical Make-Whole Fundamental Change Effective Dates, Stock Prices and the
number of Additional Shares by which the Conversion Rate will be increased per $1,000 principal amount of this Note for the Holder
that converts this Note in connection with a Make-Whole Fundamental Change having such Make-Whole Fundamental Change Effective
Date and Stock Price. In the case of a principal amount or portion of a principal amount that is not a multiple of $1,000, the
Conversion Rate will be increased by an equivalent pro rata number of shares.

 

	 	 	Stock
    Price	 
	Effective
    Date	 	$0.60	 	 	$0.76	 	 	$2.90	 	 	$3.50	 	 	$3.88	 	 	$5.00	 	 	$6.00	 	 	$8.00	 	 	$12.00	 	 	$16.00	 
	January 17, 2017	 	 	355.4918	 	 	 	236.8878	 	 	 	162.5063	 	 	 	130.9858	 	 	 	70.8763	 	 	 	39.1640	 	 	 	21.6412	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 
	January 17, 2018	 	 	355.4918	 	 	 	201.4220	 	 	 	132.1653	 	 	 	105.7891	 	 	 	57.5709	 	 	 	31.9951	 	 	 	16.7018	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 
	January 17, 2019	 	 	355.4918	 	 	 	159.9914	 	 	 	95.7987	 	 	 	75.8657	 	 	 	41.7694	 	 	 	25.8873	 	 	 	11.4030	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 
	January 17, 2020	 	 	355.4918	 	 	 	109.1105	 	 	 	51.7587	 	 	 	40.7040	 	 	 	23.0112	 	 	 	13.2302	 	 	 	5.9770	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 
	January 17, 2021	 	 	355.4918	 	 	 	2.0122	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 	 	 	0.0000	 

 

(e)          Use
of Additional Shares Table. If the Stock Price and/or Make-Whole Fundamental Change Effective Date for a Make-Whole Fundamental
Change are not set forth in the table above, then:

 

(A)         if
the Stock Price is between two Stock Prices in the table or the Make-Whole Fundamental Change Effective Date is between two Make-Whole
Fundamental Change Effective Dates in the table, the number of Additional Shares by which the Conversion Rate will be increased
for the Holder that converts this Note in connection with such Make-Whole Fundamental Change will be determined by a straight-line
interpolation between the numbers of Additional Shares set forth for the higher and lower Stock Prices listed in the table and
the earlier and later Make-Whole Fundamental Change Effective Dates listed in the table, as applicable, based on a 365- or 366-day
year, as applicable;

 

    	 	- 35 -	 

     

    

 

(B)         if
the Stock Price is greater than $8.00, subject to adjustment in the same manner as the Stock Prices set forth in the column headings
of the table, no Additional Shares will be added to the Conversion Rate; and

 

(C)         if
the Stock Price is less than $0.60 per share, subject to adjustment in the same manner as the Stock Prices set forth in the column
headings of the table, no Additional Shares will be added to the Conversion Rate.

 

Notwithstanding the foregoing, in no event
will the Conversion Rate be increased as a result of this Section 8.07 to exceed 1,673.1918 shares of Common Stock per $1,000
principal amount of this Note, subject to adjustment in the same manner, at the same time and for the same events for which the
Conversion Rate must be adjusted as set forth in Section 8.05.

 

(f)          Settlement
or Conversion. If the Holder converts this Note in connection with a Make-Whole Fundamental Change, the Company will settle
such conversion by delivering Conversion Consideration in accordance with Section 8.03; provided, however,
that notwithstanding anything to the contrary in Section 8.03, if the Holder converts this Note in connection with a Make-Whole
Fundamental Change described in clause (b)(ii) of the definition of Fundamental Change in which the holders of the Common Stock
receive only cash in consideration for their shares of Common Stock, the Company will settle such conversion by delivering to the
Holder, on the third (3rd) Business Day immediately following the Conversion Date for this Note, an amount of cash, for each $1,000
principal amount of this Note so converted, equal to the product of (i) the Conversion Rate on the Conversion Date applicable to
this Note (including any Additional Shares added to such Conversion Rate pursuant to this Section 8.07) and (ii) the Stock
Price for such Make-Whole Fundamental Change, or in the case of a principal amount or portion of a principal amount that is not
a multiple of $1,000, an equivalent pro rata amount.

 

Section
8.08         Effect of Recapitalization, Reclassification, Consolidation, Merger
or Sale.

 

(a)          General.
If any of the following events occur:

 

(1)           any
recapitalization, reclassification or change of Common Stock (other than (x) a change only in par value, from par value to no par
value or no par value to par value; or (y) changes resulting from a stock split or combination not involving the issuance of any
other class or series of securities);

 

(2)           any
consolidation, merger, combination or similar transaction involving the Company;

 

(3)           any
sale, lease or other transfer to a third party of all or substantially all of the consolidated assets of the Company and its Subsidiaries
substantially as an entirety; or

 

    	 	- 36 -	 

     

    

 

(4)         any
statutory share exchange,

 

and, in each case, as a result of which
the Common Stock would be converted into, or exchanged for, or represent solely the right to receive, stock (including one or more
series of the Common Stock), other securities, other property or assets (including cash or any combination thereof) (any such event,
a “Common Stock Change Event” and such stock, other securities, other property or assets, the “Reference
Property”, and the amount and kind of Reference Property that a holder of one share of Common Stock would be entitled
to receive on account of such Common Stock Change Event, a “Reference Property Unit”), then, notwithstanding
anything to the contrary, at the effective time of such transaction, the consideration due upon a conversion of this Note will
be determined in the same manner as if each reference to any number of shares of Common Stock in this Article 8 were instead
a reference to the same number of Reference Property Units. For these purposes, the Last Reported Sale Price of any Reference Property
Unit or portion thereof that does not consist of a class of securities will be the fair value of such Reference Property Unit or
portion thereof, as applicable, determined in good faith by the Company (or, in the case of cash denominated in U.S. dollars, the
face amount thereof).

 

If the Reference Property consists of more
than a single type of consideration (determined based in part upon any form of stockholder election), then the composition of the
Reference Property Unit shall be deemed to be (a) the weighted average, per share of Common Stock, of the types and amounts of
consideration received by the holders of Common Stock that affirmatively make such an election; or (b) if no holders of the Common
Stock affirmatively make such an election, the types and amounts of consideration actually received, per share of Common Stock,
by the holders of the Common Stock. The Company shall notify the Holder of such weighted average (if applicable) as soon as practicable
after such determination is made.

 

None of the foregoing provisions will affect
the right of the Holder to convert this Note as set forth in Section 8.01 and 8.02 prior to the effective date of
such Common Stock Change Event.

 

(b)          Notices.

 

(i)          As
soon as practicable upon learning of the anticipated or actual effective date of any Common Stock Change Event, the Company will
deliver written notice of such Common Stock Change Event to the Holder. Such Notice will include:

 

(A)         a
brief description of such Common Stock Change Event;

 

(B)         the
Conversion Rate in effect on the date the Company delivers such notice;

 

(C)         the
anticipated effective date for the Common Stock Change Event;

 

(D)         that,
on and after the effective date for the Common Stock Change Event, this Note will be convertible into Reference Property Units
and cash in lieu of fractional Reference Property Units; and

 

    	 	- 37 -	 

     

    

 

(E)         the
composition of the Reference Property Unit for such Common Stock Change Event.

 

(c)          Successive
Common Stock Change Events. If more than one Common Stock Change Event occurs, this Section 8.08 will apply successively
to each Common Stock Change Event.

 

(d)          Compliance
Covenant. The Company will not become a party to any Common Stock Change Event unless its terms are consistent with this Section
8.08.

 

Article
9

NO RIGHT OF REDEMPTION AT THE OPTION OF THE COMPANY

 

This Note will not be redeemable prior
to the Maturity Date at the Company’s election, and no sinking fund will be provided for this Note.

 

Article
10

MISCELLANEOUS

 

Section 10.01         Notices.
Any request, demand, authorization, notice, waiver, consent or communication will be in writing and delivered in Person or mailed
by first-class mail, postage prepaid, addressed as follows or transmitted by electronic transmission or other similar means of
unsecured electronic methods to the following:

 

if to the Company:

 

Xtant Medical
Holdings, Inc.

600 Cruiser
Lane

Belgrade,
MT 59714

Facsimile: (406) 388-9724

Attn: President

 

If to the Holder:

 

ROS Acquisition Offshore LP

c/o OrbiMed Advisors LLC

601 Lexington Avenue, 54th Floor

New York, NY 10022

Attention: Tadd Wessel and Christopher LiPuma

 

The Company or the Holder, by notice given
to the other in the manner provided above, may designate additional or different addresses for subsequent notices or communications.
Any notice, direction, request or demand hereunder to or upon the Holder shall be deemed to have been sufficiently given or made,
for all purposes, if it is in writing and actually received by the Holder, addressed as provided above or sent electronically in
PDF format.

 

    	 	- 38 -	 

     

    

 

Section 10.02         Separability
Clause. In case any provision in this Note will be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions will not in any way be affected or impaired thereby.

 

Section 10.03         Governing
Law and Waiver of Jury Trial. THIS NOTE WILL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK. THE COMPANY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY
IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS NOTE OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

Section 10.04         No
Recourse Against Others. A director, officer, employee or stockholder, as such, of the Company will not have any liability
for any obligations of the Company under this Note for for any claim based on, in respect of or by reason of such obligations or
their creation. By accepting this Note, the Holder will waive and release all such liability. The waiver and release will be part
of the consideration for the issuance of this Note.

 

Section 10.05         Calculations.
Except as otherwise provided in this Note, the Company will be responsible for making all calculations called for under this Note.
These calculations include, but are not limited to, determinations of the Last Reported Sale Price of the Common Stock or any other
security, accrued interest (including, for the avoidance of doubt, any Additional Interest, Default Interest or Special Interest)
payable on this Note and the Conversion Rate in effect on any Conversion Date.

 

The Company will make all calculations
in good faith and, absent manifest error, its calculations will be final and binding on the Holder. The Company will provide a
schedule of its calculations to the Holder, and the Holder is entitled to rely conclusively upon the accuracy of the Company’s
calculations without independent verification.

 

All calculations will be made to the nearest
cent or to the nearest 1/10,000th of a share, as the case may be, with 5/100,000ths rounded upward.

 

Section 10.06         Successors.
All agreements of the Company in this Note will bind its successors.

 

Section 10.07         Table
of Contents; Headings. The table of contents and headings of the articles and sections of this Note have been inserted for
convenience of reference only, are not intended to be considered a part hereof, and will not modify or restrict any of the terms
or provisions hereof.

 

Section 10.08         Submission
to Jurisdiction. The Company: (a) agrees that any suit, action or proceeding against it arising out of or relating to this
Note as the case may be, may be instituted in any U.S. federal court with applicable subject matter jurisdiction sitting in The
City of New York; (b) waives, to the fullest extent permitted by applicable law, any objection which it may now or hereafter have
to the laying of venue of any such suit, action or proceeding, and any claim that any suit, action or proceeding in such a court
has been brought in an inconvenient forum; and (c) submits to the nonexclusive jurisdiction of such courts in any suit, action
or proceeding.

 

    	 	- 39 -	 

     

    

 

Section 10.09         Legal
Holidays. If the Maturity Date or any Interest Payment Date or Fundamental Change Repurchase Date is not a Business Day (which,
solely for the purposes of any payment required to be made on this Note on any such date will be deemed not to include any day
on which the office where the place of payment is authorized or required by law to close), then any action to be taken on such
date need not be taken on such date, but may be taken on the immediately following Business Day, and no interest on such payment
will accrue as a result of such delay.

 

Section 10.10         No
Security Interest Created. Nothing in this Note, expressed or implied, will be construed to constitute a security interest
under the Uniform Commercial Code or similar legislation, as now or hereafter enacted and in effect, in any jurisdiction.

 

Section 10.11         Benefits
of Note. Nothing in this Note, expressed or implied, will give to any Person, other than the parties hereto,
and their successors hereunder, any benefit or any legal or equitable right, remedy or claim under this Note.

 

Section 10.12         Withholding
Taxes. The Holder agrees, and each beneficial owner of an interest in this Note, by its acquisition of such interest, is deemed
to agree, that if the Company or other applicable withholding agent pays withholding taxes or backup withholding on behalf of the
Holder or beneficial owner, as applicable, as a result of an adjustment to the Conversion Rate, then the Company or other applicable
withholding agent, as applicable, may, at its option, set off such payments against payments of cash and shares of Common Stock
on this Note.

 

Section 10.13         Amendment
and Waiver. With the written consent of the holders of at least a majority of the Series then outstanding (including consents
obtained in connection with a repurchase of, or tender offer or exchange offer for, notes of the Series), the Company, may amend
the notes of the Series or waive compliance with any provision of the notes of the Series; provided, however, that,
without the consent of each affected holder, no amendment to the notes of the Series, or waiver of any provision of the notes of
the Series, may:

 

(a)          reduce
the principal amount of, or change the Maturity Date of, any note of the Series;

 

(b)          reduce
the rate of, or extend the stated time for payment of, interest on any note of the Series;

 

(c)          reduce
the Fundamental Change Repurchase Price of any note of the Series or change the time at which, or the circumstances under which,
the notes of the Series may, or will be, repurchased;

 

(d)          impair
the right of any holder to institute suit for any payment on any note of the Series, including with respect to any consideration
due upon conversion of a note of the Series;

 

(e)          make
any note of the Series payable in a currency other than that stated in such note;

 

    	 	- 40 -	 

     

    

 

(f)          make
any change that impairs or adversely affects the conversion rights of any holder under Section 8 or otherwise reduces the
number of shares of Common Stock, the amount of cash or any other property receivable by a holder upon conversion;

 

(g)          change
the ranking of the notes of the Series;

 

(h)          make
any change to any amendment, modification or waiver of a provision of a note of the Series that requires the consent of each affected
holder of notes of the Series; or

 

(i)           reduce
the percentage of the aggregate principal amount of then outstanding notes of the Series whose holders must consent to an amendment
or modification of any note of the Series or a waiver of a past Default.

 

It will not be necessary for the consent
of the holders under this Section 10.13 to approve the particular form of any proposed amendment or modification, but it
will be sufficient if such consent approves the substance of such proposed amendment or modification.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

    	 	- 41 -	 

     

    

 

IN WITNESS WHEREOF, the undersigned have
executed this Note as of the day and year first written above.

 

		Xtant
    Medical Holdings, Inc.
	 	 	 
	 	By:	/s/
    Daniel Goldberger
	 	 	Name:	Daniel Goldberger
	 	 	Title:	Chief Executive Officer

 

[Signature Page
to Convertible Promissory Note]

 

    	 	 	 

     

    

 

EXHIBIT A

 

CONVERSION NOTICE

 

XTANT MEDICAL HOLDINGS, INC.

6.00% CONVERTIBLE SENIOR NOTE DUE 2021

 

To convert this Note, check the box £

 

To convert the entire principal amount
of this Note, check the box £

 

To convert only a portion of the principal
amount of this Note, check the box £ and here specify the principal amount
to be converted:

 

	$	 	 

 

ROS
Acquisition Offshore LP

  

	By:	 	 
	 	Authorized Signatory	 

 

    	 	 	 

     

    

 

EXHIBIT B

 

FUNDAMENTAL CHANGE REPURCHASE NOTICE

 

Xtant Medical Holdings, Inc.

600 Cruiser Lane

Belgrade, MT 59714

Attention: General Counsel

 

The undersigned registered owner of this
Note hereby acknowledges receipt of a notice from Xtant Medical Holdings, Inc. (the “Company”) as to the occurrence
of a Fundamental Change with respect to the Company and specifying the Fundamental Change Repurchase Date and requests and instructs
the Company to pay to the Holder hereof in accordance with the applicable provisions of this Note (1) the entire principal amount
of this Note, or the portion thereof below designated; and (2) if such Fundamental Change Repurchase Date does not occur during
the period after a Regular Record Date and on or prior to the corresponding Interest Payment Date, accrued and unpaid interest,
if any, thereon to, but excluding, such Fundamental Change Repurchase Date.

 

Principal amount to be repaid (if less
than all): $               ,000

 

ROS
Acquisition Offshore LP

  

	By:	 	 
	Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]